



# Modeling Host-Pathogen Interactions in the Context of the Microenvironment: Three-Dimensional Cell Culture Comes of Age

 Jennifer Barrila,<sup>a</sup>  Aurélie Crabbé,<sup>b</sup> Jiseon Yang,<sup>a</sup> Karla Franco,<sup>a</sup> Seth D. Nydam,<sup>a</sup> Rebecca J. Forsyth,<sup>a,†</sup> Richard R. Davis,<sup>a</sup> Sandhya Gangaraju,<sup>a</sup> C. Mark Ott,<sup>c</sup>  Carolyn B. Coyne,<sup>d</sup> Mina J. Bissell,<sup>e</sup>  Cheryl A. Nickerson<sup>a,f</sup>

<sup>a</sup>Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, Arizona, USA

<sup>b</sup>Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium

<sup>c</sup>Biomedical Research and Environmental Sciences Division, NASA Johnson Space Center, Houston, Texas, USA

<sup>d</sup>Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

<sup>e</sup>Division Biological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, California, USA

<sup>f</sup>School of Life Sciences, Arizona State University, Tempe, Arizona, USA

**ABSTRACT** Tissues and organs provide the structural and biochemical landscapes upon which microbial pathogens and commensals function to regulate health and disease. While flat two-dimensional (2-D) monolayers composed of a single cell type have provided important insight into understanding host-pathogen interactions and infectious disease mechanisms, these reductionist models lack many essential features present in the native host microenvironment that are known to regulate infection, including three-dimensional (3-D) architecture, multicellular complexity, commensal microbiota, gas exchange and nutrient gradients, and physiologically relevant biomechanical forces (e.g., fluid shear, stretch, compression). A major challenge in tissue engineering for infectious disease research is recreating this dynamic 3-D microenvironment (biological, chemical, and physical/mechanical) to more accurately model the initiation and progression of host-pathogen interactions in the laboratory. Here we review selected 3-D models of human intestinal mucosa, which represent a major portal of entry for infectious pathogens and an important niche for commensal microbiota. We highlight seminal studies that have used these models to interrogate host-pathogen interactions and infectious disease mechanisms, and we present this literature in the appropriate historical context. Models discussed include 3-D organotypic cultures engineered in the rotating wall vessel (RWV) bioreactor, extracellular matrix (ECM)-embedded/organoid models, and organ-on-a-chip (OAC) models. Collectively, these technologies provide a more physiologically relevant and predictive framework for investigating infectious disease mechanisms and antimicrobial therapies at the intersection of the host, microbe, and their local microenvironments.

**KEYWORDS** 3-D, 3D, RWV, rotating wall vessel, gut-on-a-chip, host-microbe interaction, host-pathogen interactions, mechanotransduction, organ-on-a-chip, organoid

Mucosal surfaces lining the gastrointestinal, respiratory and urogenital tracts continuously interface with the external environment and serve as a barrier against pathogens, commensals, chemicals, drugs, and toxins. These tissues possess a complex architecture with multiple cell types organized into three-dimensional (3-D) structures that facilitate tissue-specific functions. The biological, chemical, and biomechanical characteristics that define microenvironmental niches along these surfaces provide the

Accepted manuscript posted online 4 September 2018

**Citation** Barrila J, Crabbé A, Yang J, Franco K, Nydam SD, Forsyth RJ, Davis RR, Gangaraju S, Ott CM, Coyne CB, Bissell MJ, Nickerson CA. 2018. Modeling host-pathogen interactions in the context of the microenvironment: three-dimensional cell culture comes of age. *Infect Immun* 86:e00282-18. <https://doi.org/10.1128/IAI.00282-18>.

**Editor** Anthony T. Maurelli, University of Florida

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

Address correspondence to Cheryl A. Nickerson, Cheryl.Nickerson@asu.edu.



† Deceased 15 October 2017.

structure and context in which infection takes place. Pathogens have adapted to detect specific host structures, polarity, and changes in local environmental stimuli (pH, temperature, oxygen, nutrients, hormones, physical forces, etc.) to know where and when to activate specific virulence programs during different infection stages (1–7). A major challenge in tissue engineering for infectious disease research is recreating *in vivo* spatiotemporal properties of dynamic 3-D microenvironments to more accurately model host-pathogen interactions in the laboratory.

Historically, infectious disease has been commonly studied *in vitro* by assessing the interaction of a single microbe with a single host cell type, with the latter grown as flat 2-D monolayers. This reductionist approach has enabled important discoveries and advanced our understanding of mechanisms that underlie infection and disease. However, the study of disease in isolation or out of context can change the native behavior of both host and microbe, thus creating a barrier for researchers to correlate *in vitro* and *in vivo* responses. In this data-rich period where multiple -omics technologies are being synergistically applied for unparalleled insight into host-pathogen interactions, it is critical to consider the context in which these investigations are performed. Reconstructing host microenvironments is key, including 3-D tissue architecture, multicellular complexity, microbiota composition/localization, oxygen tension, transport processes, and biomechanical forces (e.g., fluid shear, stretch, compression) (1, 8–11). Within this context, *in vitro* models are positioned along a continuum between 2-D and 3-D, with flat monolayers of a single cell type representing the most basic system and more complex models located further down the spectrum that recreate multiple aspects of the native tissue microenvironment (Fig. 1). Since tissues and organs function in a 3-D context, consideration of proper structure is essential for development of models that better mimic *in vivo* responses. Since no current *in vitro* model fully accomplishes this task, multidisciplinary teams of biologists, engineers, physicists, mathematicians, and clinicians are creatively working together to develop next-generation 3-D models with enhanced predictive capabilities to open new avenues for clinical translation.

Present-day 3-D culture techniques result from a series of progressive advances in tissue engineering over the past century to better mimic the native structure and microenvironment of normal and diseased tissues (reviewed in reference 12). Indeed, long ago the cancer research community recognized that appropriate modeling of the 3-D microenvironment is important for mimicking disease, leading to development and application of 3-D organoid models developed within or on top of extracellular matrix (ECM) (12–16). The bidirectional exchange of biological and physical signals between cells and their microenvironment regulates cell structure/function and is largely manifested by tensile connections between ECM, cell surface receptors (e.g., integrins), and the cytoskeleton to transduce signals to and from the nucleus (17–31). This structural network is also engaged by certain invasive pathogens (e.g., *Salmonella*, *Shigella*, *Listeria*, rotavirus, and influenza virus) that hijack and remodel host cell architecture to facilitate their internalization, intracellular trafficking, and/or dissemination (9, 32–34). Similarly, we and others have demonstrated that bacteria also respond to biomechanical forces like fluid shear, which can regulate virulence, gene expression, and/or stress responses (1–5, 35–47). Indeed, the discovery of biomechanical forces as environmental regulators of microbial pathogenesis was made by our team almost 2 decades ago with the finding that fluid shear forces globally reprogram *Salmonella* gene expression, stress responses, and virulence (35). Fluid shear also plays a central role in regulating a number of host responses, including differentiation (48–50).

Although 3-D models have long been applied for cancer research (12–16), they remained largely unincorporated by the infectious disease community until the late 1990s and early 2000s. As expected for many new ideas in an established field, the use of 3-D models to study host-pathogen interactions was initially met with skepticism. The first reports of 3-D models to study viral infections were by Long et al. in 1998 (rhinovirus) and bacterial infections by Nickerson et al. in 2001 (*Salmonella enterica* serovar Typhimurium) (11, 51). Recently, infectious disease researchers have broadly



**FIG 1** Recreating the complex intestinal microenvironment to study host-pathogen interactions. (A) *In vitro* model advancement from 2-D to 3-D by incorporation of physiological factors to better mimic the *in vivo* environment. (Intestinal lumen, cell, intestine, and intestinal microbe images are republished from references 398 to 401, respectively, with permission of the publisher.) (B) Three-dimensional approaches routinely used to develop advanced intestinal models: (a) RWV bioreactor, (b) (republished from reference 307 with permission of the publisher), and (c) OAC (republished from reference 344 with permission of the publisher). (d) Scanning electron micrograph (SEM) showing an RWV colon model. (Republished from *PLoS One* [152].) (e) Light micrograph of an enteroid model. (Republished from *Physiological Reports* [240].) (f) SEM of a gut-on-a-chip model (republished from reference 341 with permission of the publisher). (g) Oxygen-dependent host cell colocalization of *S. Typhimurium* in an RWV 3-D coculture model of intestinal epithelium and macrophages. Following aerobic culture of bacteria, no macrophages were found, but following microaero-

(Continued on next page)

embraced 3-D models for studying pathogenesis mechanisms, for biomarker discovery, and for drug candidate screening. In this review, we highlight key microenvironmental factors to consider when selecting *in vitro* 3-D intestinal models to study host-pathogen interactions. We focus on three key technologies for model development, (i) the rotating wall vessel (RWV) bioreactor, (ii) ECM-embedded/organoid models, and (iii) gut-on-a-chip models, and propose a vision for future model advancements. We also provide proper historical context for use of 3-D cell cultures in studying host-pathogen interactions, which is finally gaining a critical mass of scientists who understand and appreciate the value of studying disease in the proper context of tissue form and function.

### MICROENVIRONMENTAL CUES IN HOST-MICROBE INTERACTIONS

Mucosal tissue function and homeostasis are meticulously controlled by complex bidirectional interactions between cells and their microenvironment (15, 20, 25, 27–29, 52–55). The microenvironment includes 3-D tissue architecture, multiple cell types, ECM, innate immunity mediators, indigenous microbiota, and physical forces. These factors are regulatory signals for mucosal pathogens and may be beneficial or detrimental for infection (1–5, 8, 35–45, 47, 56–64). Below we address key cellular, biochemical, and biophysical cues that dictate infection outcome and are important considerations when modeling host-enteric pathogen interactions.

**Cellular factors.** Intestinal mucosal epithelium contains an array of specialized epithelial and immune cells that work in synergy to protect against infection by (i) serving as a barrier against luminal toxins, commensals, and pathogens, (ii) sampling microbial antigens, and (iii) recruiting innate and adaptive immune effectors (65). The intestine contains multiple epithelial cell types, including enterocytes (absorptive functions), enteroendocrine cells (hormone secretion), Paneth cells (antimicrobial production), goblet cells (mucin production), M cells (luminal antigen sampling/induction of mucosal immunity), Tuft cells (Th2 immunity), and cup cells (unknown function) (66, 67). The intestine also contains immune cells for innate and adaptive responses to pathogen attack, including macrophages, dendritic cells, and T and B cells, including those organized in lymphoid structures termed Peyer's patches, sites of induction of mucosal immunity. As the body's largest immune organ, the composition, organization, and function of the intestine vary by region and consist of integrated cross-communication networks of different cell types and effectors critical for protection against pathogens (described in references 59, 65, and 68 to 72).

Epithelial cell polarity establishes barrier function, regulates uptake/transport of nutrients, and maintains epithelial architecture (65, 73–75). In the intestine, apical surfaces face the lumen and regions between villi/folds, lateral surfaces face adjacent cells, and basal surfaces face the basement membrane and lamina propria. Along Peyer's patches and isolated lymphoid follicles, the basal side of the follicle-associated epithelium overlies a subepithelial dome region containing a mixture of immune cells (76). The distinct biochemical composition (e.g., protein and lipid) of apical and basolateral surfaces facilitates their specific functions (75). Given that many pathogens have evolved to recognize surface-specific molecules for attachment and/or to disrupt barrier integrity to enable their uptake and dissemination (6, 74, 77–79), appropriately modeling polarity *in vitro* is critical, as pathogens infect host cells differently depending on whether they are polarized or nonpolarized (80–83). Maintaining barrier integrity requires proper expression and localization of tight and adherens junctions. Adherens junctions are mediated by E-cadherin and catenin interactions, while tight junctions are

#### FIG 1 Legend (Continued)

bic culture, macrophages were present and either were empty (left inset) or contained internalized bacteria (right inset). Macrophages (CD45; yellow), *Salmonella* (green; white when overlaid with CD45), and nuclei (4',6-diamidino-2-phenylindole [DAPI]; blue) are visible. Scale bar = 10  $\mu$ m. (Republished from *npj Microgravity* [171].) (h) iHIOs injected with *E. coli* O157:H7. Nuclei (blue), neutrophils (CD11b; red), and *E. coli* (green) are visible. Scale bar = 100  $\mu$ m. (Republished from *PLoS One* [260].) (i) CVB-infected gut-on-a-chip. CVB (green), F-actin (red), and nuclei (blue) are visible. (Republished from *PLoS One* [343].)

composed of transmembrane proteins (e.g., claudins and occludins) and cytoplasmic plaque proteins (e.g., zonula occludens). While generally protective, junctional complexes are also exploited by pathogens to facilitate invasion (74) and some enteric viruses utilize receptors localized to these junctions (77, 78).

Another major cellular component encountered by enteric pathogens is the diverse microbial community—termed microbiota (referring to microorganisms) or microbiome (referring to microbial genomes). The intestinal tract contains prokaryotes, viruses, archaea, and eukaryotes, some of which protect the host against pathogen colonization by a variety of mechanisms, including epithelial cell turnover, mucin synthesis, and triggering bacterial sensors on host cells (84–86). Reciprocal interactions between host and microbiota contribute to tissue function and homeostasis and determine microbiota composition, thereby playing an important role in infection and disease (87). For example, members of the intestinal microbiota regulate production of antimicrobial peptides by Paneth cells (88) and shape immune responses by regulating numbers, subsets, and/or functions of T, B, and myeloid cells (65). Microbiota-induced changes in immunity also determine intestinal microbiota composition (85, 89).

The intestinal microbiota is comprised of  $\sim 10^{14}$  bacteria ( $>1,000$  species), with *Firmicutes* and *Bacteroidetes* most abundant (90–93). Interpersonal variation in intestinal microbiome occurs, with each individual carrying a subset of the total known microbiome (94). Temporal and spatial variation occurs throughout the intestinal tract (95, 96). Increasing data suggest a relationship between an imbalanced intestinal microbiome and various diseases, including obesity, inflammatory bowel disorders, and cancer (97). The importance of the gut microbiota to health is highlighted by successful clinical application of fecal microbiota transplants from healthy individuals to patients with recurrent, antibiotic-resistant *Clostridioides difficile* infections (98–100).

**Biochemical cues.** Mucosal tissues contain an array of small molecules, including innate defense mediators that target pathogens and regulate downstream host defenses. Intestinal mucus harbors compounds from the innate and adaptive systems that protect against microbial insult, including digestive enzymes (e.g., lysozyme), lactoferrin, antimicrobial peptides, complement, and antibodies (e.g., secretory immunoglobulin A [sIgA]) (65). In addition, cells of the innate defense system respond to pathogen-associated molecular patterns (PAMPs) using pathogen recognition receptors (PRRs). Depending on the pathogen, PRR-mediated signal transduction results in different cellular outcomes (e.g., cell proliferation, apoptosis, antimicrobial peptide production, autophagy, and cytokine secretion). Cytokine production leads to recruitment of innate and adaptive immune effectors to the infection site, representing a bridge between these two arms of immunity (65, 101).

Mucins are complex mixtures of high-molecular-weight, glycosylated macromolecules that bind and remove pathogens and their products (7, 101). Enteric pathogens sense and respond to cues within mucus and overcome this barrier to reach underlying epithelium (7). Normal intestinal mucus consists of two layers: an outer layer colonized by microbes and a sterile inner layer (102–104). The composition and thickness of these mucin layers vary throughout intestinal regions to accommodate their different functions and microbial burdens. Within the small intestine, the inner and outer mucosal layers are thinner to facilitate nutrient absorption, with thicker regions found toward the ileum, where microbial burden is heavier (7). In the colon, both layers are thicker to accommodate the burden of several trillion commensals (7). The presence of sIgA and other mucin antimicrobials also serves to reduce bacterial colonization (105).

The ECM is another key contributor to tissue homeostasis. The ECM has historically been neglected as a signaling entity, but seminal discoveries have revealed the central role of ECM in regulating tissue architecture/function (20, 53). The ECM is a three-dimensional noncellular scaffold comprised of proteins (e.g., collagens, elastins, laminins, and fibronectins), proteoglycans, and water. Two main types of ECM include (i) interstitial connective tissue matrix, which serves as a cellular scaffold, and (ii) basement membrane matrix, which separates epithelium from interstitium (106, 107). ECM com-

ponents also serve as ligands for cell receptors like integrins, which transduce physical forces into biological responses (mechanotransduction). Additionally, immune responses are mediated through interactions with the ECM (107, 108). Furthermore, the ECM controls availability/release of growth factors and other signaling molecules (hormones and cytokines) (107). The complexity, composition, and structure of ECM are highly dynamic and specific (as are the biochemical gradients it contains) and depend on tissue type, developmental stage, and health/disease state (107).

**Biophysical forces.** The role of physical forces in cell and tissue development/function is as important as those of genes and biochemical signals (28, 109). Physical forces regulate cell proliferation, differentiation, and homeostasis (110, 111). Forces experienced by intestinal cells include fluid shear, pressure (112), and contractile peristalsis of muscles (113). Hydrodynamic calculations suggest that fluid shear forces on the exposed epithelial brush border microvilli are ~200 times greater than those between microvilli ( $<0.01$  dynes/cm<sup>2</sup>) (114).

The cytoskeleton and its linkage with the ECM play an essential role in enabling cells to sense and respond to biophysical forces. While the governing role of the ECM as a dynamic signaling entity that regulates tissue form/function is now appreciated, it was initially considered a purely static scaffold. However, tissue-specific architecture and function are regulated by the biophysical properties of the ECM (20, 115, 116), which exerts physical influences transduced by cell surface receptors through the cytoskeleton to the nucleus to ultimately alter cellular and molecular properties. These structural networks are critical for regulating cell shape/architecture and have been modeled using the principle of tensegrity, which refers to structures that are stabilized under continuous tension by balancing opposing tension and compression forces (27–29, 31). The integration of biophysical forces across cells and tissues using this structural network regulates a wide range of biological processes (e.g., cell proliferation, apoptosis, differentiation, adhesion, migration, gene expression, and architecture) (8, 20, 21, 23, 25, 27, 29–31, 55, 117). Accordingly, ECM composition and stiffness are critical regulators of cellular responses (118, 119). These properties are continuously remodeled through the process of “dynamic reciprocity” (17, 20, 53, 117), theorized by Bissell in 1982 to explain how signaling between the ECM and nucleus regulates tissue function. This laid the foundation for modern 3-D cell culture approaches used today (20, 107, 120). Not surprisingly, pathogen-ECM interactions play an important role in mediating infection (121–126). In addition to impacting the host, physical forces also globally alter bacterial gene expression, stress responses, and virulence in unexpected ways to contribute to infection (5, 36–40, 47, 62–64).

### MODELING THE MICROENVIRONMENT: 3-D MODELS FOR INFECTIOUS DISEASE

Several cell culture systems exist for the development and application of 3-D models of human tissues for infectious disease research, including the RWV bioreactor, ECM-embedded scaffolds (e.g., ECM extracts, purified ECM, or synthetic/semisynthetic hydrogels), and organ-on-a-chip (OAC) models. The choice of system to use depends on several factors, including the experimental question being addressed, technical complexity, and cost and expertise for model development. Different cell types in the native tissue (including immune cells) can be cocultured in these models to further enhance physiological relevance. Additionally, a single epithelial cell type can spontaneously differentiate into multiple epithelial cell types normally found in the parental tissue and undergo self-assembly into tissue-like structures using all of these 3-D technologies. To date, most *in vitro* infection studies have been performed using cell lines; however, there is a push to develop models using either primary or stem cells to better mimic the native tissue. To explore the integration of different environmental signals in regulating infection, a hierarchical series of increasingly complex 3-D model systems comprised of different cell types can be developed and applied in parallel under differing experimental conditions (e.g., different oxygen tensions and physical forces).

**RWV-derived 3-D models.** The RWV bioreactor is an optimized form of suspension culture that facilitates formation of self-organizing 3-D tissue-like aggregates by allow-

ing cells the spatial freedom to colocalize and self-assemble based on natural affinities within a low-fluid-shear environment (Fig. 1B, panel a) (8, 127). Fluid shear influences cell proliferation, differentiation, morphology, and function (30, 114, 128–140). Models developed within the dynamic RWV environment experience excellent mass transfer of nutrients/wastes and exhibit enhanced structure, differentiation, function, and multicellular complexity relative to 2-D monolayers (11, 80, 141–154). Along these lines, observations from the 1970s showed that flotation of collagen gels led to a more permissive environment for cellular differentiation (12, 155, 156). Moreover, the low-fluid-shear environment in the RWV is also physiologically relevant to that encountered by pathogens in low-shear regions of the infected host, including the intestine (38, 114, 129–131). Accordingly, the RWV is also used to culture pathogens to study the role of fluid shear and mechanotransduction in regulating microbial pathogenesis and host-pathogen/commensal interactions (1, 35–41, 45–47, 62, 64, 145, 157–167).

The RWV is among the most extensively used approaches to develop 3-D models to study host-pathogen interactions. It was the first technology used to develop 3-D models for infection studies with bacterial (*Salmonella*) and viral (rhinovirus) pathogens (11, 51). A range of RWV-derived 3-D models have been developed using cell lines, stem cells, and/or primary cells, including small and large intestine (11, 80, 141, 143, 145, 146, 152, 168–177), lung (144, 147, 178–182), liver (148, 153, 174, 183, 184), bladder (8, 185–187), reproductive tissue (149–151, 188–190), heart (191–193), prostate (142, 186, 194), pancreas (195, 196), nervous tissue (182, 197–199), blood-brain barrier (200), skin (201), eye (202), bone, joint, or disc (203–207), and tonsil (208), among others. These studies demonstrated that RWV-derived models exhibit enhanced *in vivo*-like characteristics, including spontaneous differentiation into multiple cell types that self-organize into 3-D structures (Fig. 1B, panel d), polarization, appropriate expression/localization of adherens/tight junctional complexes, metabolic product secretion, gene expression, cytokine production, responses to antimicrobials and microbial products, support of commensals, and/or susceptibility to infection (8, 11, 80, 141–153, 168–194, 197–208). In addition, RWV models have been advanced to incorporate immune cells to study their role in host-microbe interactions (171, 175, 177, 180).

Models are typically initiated by harvesting monolayers, combining cells with porous ECM-coated microcarrier scaffolds, and loaded into the RWV. Scaffold and ECM porosity allows the basal side of cells to experience autocrine/paracrine communications, aiding cellular differentiation/responses in a manner reflecting *in vivo* tissues. This differs from monolayers where cells proliferate on impermeable surfaces, thus hindering proper communications across apical and basolateral surfaces. Additionally, models may be developed scaffold free or using nonmicrocarrier scaffolds (e.g., decellularized tissues) for transplantation (179, 181, 209). Once developed, distribution of 3-D models into multiwell plates lends to their experimental tractability for infection assays, as their structural/functional integrity remains intact following seeding. Alternatively, pathogens or compounds can be directly added to the RWV to study interactions under physiological fluid shear. One key advantage of RWV culture is the production of large numbers of cells ( $\sim 10^7$  to  $10^8$  per culture). Below we discuss RWV-derived 3-D models of human intestinal mucosa.

**RWV-derived intestinal models.** We began using the RWV to engineer 3-D models of human intestine for infection studies in the late 1990s after realizing that available models for studying bacterial pathogenesis lacked multiple aspects of the *in vivo* microenvironment (11). RWV-derived 3-D models have enabled the study of host-microbe interactions relevant to different regions of the intestinal tract, including the small intestine (11, 169) and colon (80, 143, 145, 146, 152, 171, 172, 175, 177). Imaging of these models revealed enhanced 3-D architecture relative to monolayers, including the presence of extensive 3-D folds and microvilli, that more closely resembled what is observed *in vivo* (Fig. 1B, panel d). These 3-D models are essentially “inside-out” such that the apical/luminal side faces the media and the basal side faces the scaffold, allowing for straightforward introduction of pathogens, toxins, and antimicrobials at

the apical surface, as commonly occurs *in vivo*. Collectively, these models have shown physiologically relevant expression and localization of key cellular components, including junctional proteins (e.g., ZO-1, occludin, symplekin, E-cadherin,  $\beta$ -catenin, and desmosomes), secretion of basal lamina components (e.g., collagen types II, III, and IV, laminin, vimentin, and fibronectin), brush border formation with villin, and/or mucus secretion (11, 80, 143, 145, 146, 152, 169, 171, 172, 175, 177). Spontaneous cellular differentiation into multiple lineages found in the intestinal epithelium is also observed, including enterocytes, M cells, goblet cells, and/or Paneth cells (enteroendocrine cells were not evaluated) (11, 80, 146, 152, 171, 175). The presence of multiple cell types within a model (e.g., epithelial and immune cells) enables study of their combined effects on infection, and in particular, pathogen colocalization patterns with different cell types. An example is described below in which an advanced 3-D RWV coculture model that combined human colonic epithelium with phagocytic macrophages was used to study infection by different *Salmonella* pathovars (171). Primary human lymphocytes have also been incorporated in a 3-D coculture model of intestinal epithelium to study *Salmonella* infection (175).

RWV-derived intestinal models have contributed to the study of a variety of pathogens, such as *S. Typhimurium* (including multidrug resistant ST313), *Salmonella enterica* serovar Typhi, enteropathogenic *Escherichia coli* (EPEC), enterohemorrhagic *E. coli* (EHEC), *Cryptosporidium parvum*, and human enteroviruses, including coxsackievirus B (CVB) and poliovirus (11, 80, 143, 145, 146, 152, 171, 172, 175). Studies with *S. Typhimurium* using 3-D models of small and large intestine displayed marked differences from monolayers in colonization, tissue morphology, apoptosis, and prostaglandin and cytokine expression (11, 80, 152). The responses of these 3-D intestinal models to *S. Typhimurium* challenge were highly predictive of *in vivo* responses in humans/animals (11, 80, 152), including rapid repair of the small intestine (initial site of *Salmonella* pathogenesis) and significant damage to the colon (primary site of pathogenesis) (210). These models were also the first *in vitro* systems to challenge the widely accepted paradigm established using monolayers that the *Salmonella* pathogenicity island 1 (SPI-1) type 3 secretion system (T3SS) is required for invasion of intestinal epithelium (80, 152). Historically, studies with monolayers contradicted *in vivo* observations wherein successful animal infections were possible with T3SS SPI-1 mutants (211, 212), and clinical isolates of *Salmonella* lacking SPI-1 function were isolated from foodborne disease outbreaks in patients experiencing gastroenteritis (213). Using a 3-D intestinal model comprised solely of epithelial cells, Radtke et al. demonstrated that SPI-1 mutants and a *Salmonella* mutant lacking all known T3SSs (SPI-1, SPI-2, and the flagellar system) still exhibited high levels of invasion relative to the wild type (although approximately 0.5 to 1 log lower) (152). As expected, in monolayers these mutants exhibited little to no invasion (<10 CFU), a finding which does not reflect *in vivo* observations (152). Thus, for the first time, an *in vitro* intestinal epithelial model was able to parallel *in vivo* results by supporting *Salmonella* invasion independently of SPI-1. These findings demonstrate the enhanced capability of RWV models to predict *in vivo*-like pathogenic mechanisms.

Host-pathogen-commensal and host-commensal interactions have also been investigated using RWV 3-D intestinal models (172, 177). Commensal microbes naturally enhance intestinal mucosal barrier function against pathogen colonization through complex mechanisms not yet fully characterized (214). Naturally occurring probiotic strains of bacteria are being exploited as a strategy against pathogens to combat ongoing problems of antibiotic resistance. Treatment of a 3-D intestinal model with *Lactobacillus reuteri* or its antimicrobial metabolite, reuterin, before or after challenge with *S. Typhimurium* reduced adhesion, invasion, and intracellular survival of this pathogen compared to findings for untreated cells (172). This was the first study to report the effect of reuterin on the enteric infection process for any mammalian cell type. A 3-D intestinal coculture model containing immune cells was used to profile responses to both free secretory IgA (sIgA) and sIgA complexed with a commensal strain of *E. coli* (177). Application of free sIgA to the model induced upregulation of



MUC2, interleukin 8 (IL-8), and polymeric immunoglobulin receptor (pIgR) secretion. When sIgA was complexed with *E. coli* and applied to the model, these responses were downregulated relative to models treated with free sIgA.

Barrila et al. reported advancement of a 3-D HT-29 colon model to include phagocytic macrophages, thereby improving its physiological relevance to study aspects of the innate immune response to infection (171). Characterization of this coculture model revealed macrophages integrated between and underneath epithelial cells while preserving epithelial tight junctions and the presence of multiple epithelial cell types, including enterocytes, M cells, and goblet cells (171). Macrophage phagocytosis was confirmed by evaluating their ability to engulf inert, bacterium-sized beads. The contribution of macrophages to *Salmonella* infection was assessed using *S. enterica* pathovars with differing host tropisms and disease phenotypes, including the well-studied sequence type 19 (ST19) *S. Typhimurium* strain SL1344, which causes disease in a wide range of hosts, the multidrug-resistant ST313 *S. Typhimurium* strain D23580, and the human-specific *S. Typhi* strain Ty2. Although classified as *S. Typhimurium*, ST313 strains display genome degradation similar to that of human-adapted *S. Typhi* and are associated with devastating epidemics of blood-borne infections in sub-Saharan Africa (215). Bacteria were cultured aerobically or microaerobically prior to infection to simulate oxygen environments encountered before and during intestinal infection. Colonization of all strains was reduced in the coculture model containing macrophages relative to the epithelial model, indicating antimicrobial function of macrophages. Although ST313 strains are considered highly invasive due to the systemic infection they cause, D23580 was not highly invasive in the 3-D models but instead exhibited enhanced survival/replication, thus providing clues as to what drives this organism's pathogenicity. Pathovar- and oxygen-specific differences in host cell colocalization patterns were also observed (Fig. 1B, panel g), indicating the ability of these advanced models to distinguish between closely related *Salmonella* serovars, thus providing a unique advantage over models composed of a single cell type (171).

RWV-derived intestinal models are also valuable for investigating host-pathogen interactions for which conventional cultivation strategies are unable to adequately model *in vivo* complexity. Recently, a 3-D colonic model was applied to study human CVB (146), a pathogen for which *in vitro* and *in vivo* models may not fully model the enteral infection route in humans (146, 216–219). Comparisons between polarized 2-D and 3-D cells revealed that the 3-D model displayed an enhanced number of viral particles secreted into the media at early stages of the viral life cycle, which did not coincide with increased host cell destruction relative to monolayers (146). These data suggest that 3-D models exhibit an enhancement in nonlytic release of viral particles, which might result from morphological changes (e.g., enhanced brush border formation) in 3-D cells. Similarly, another 3-D colonic model was used to study *Cryptosporidium parvum*, a parasite for which there is a lack of physiologically relevant *in vitro* and *in vivo* models (143). Following *C. parvum* infection, morphological changes were observed that were consistent with those from colonic biopsy specimens of infected patients (143). These studies further emphasize the critical importance of model complexity and physiological relevance as determinants in enabling host-pathogen interactions.

In summary, 3-D RWV intestinal models are powerful tractable research tools that advance the study of host-pathogen interactions. These models can be modularly altered to incorporate different cell types (including patient-derived cells), ECM, commensal microbiota, physical forces, etc., akin to *in vivo* scenarios, increasing their relevance. Their tissue-like architecture, differentiation and polarization, enhanced expression/localization of junctional proteins, and mucin production are necessary components of an effective barrier to invading pathogens.

**Limitations and future directions of RWV-derived 3-D models.** Although many key structural/functional characteristics of parental tissues have been successfully recapitulated using RWV models, several limitations remain. The full extent of 3-D

architecture, multicellular complexity, and array of physical forces of *in vivo* tissues has not yet been attained. Ongoing studies are further enhancing these features, plus incorporating patient-specific immune cells and fecal microbiota, and achieving vascularization and innervation. Models can be costly due to high medium consumption required for culturing large numbers of cells; however, researchers can scale down. Although bead porosity facilitates apical/basal cytokine secretion and there is excellent access to the apical side of the models, there is currently an inability to sample the basal side. This also prevents measurement of transepithelial electrical resistance (TEER), which measures electrical resistance across a monolayer as a proxy for assessing barrier integrity (220). The technique involves using two electrodes, one in contact with cells on a semipermeable membrane (e.g., apical side) and the other in a different chamber containing culture medium (e.g., basal side). With most RWV models grown on tiny ( $\sim 175 \mu\text{m}$ ) microcarrier beads, these measurements are not currently possible with off-the-shelf technology. This challenge will likely be surmounted with custom electrode design to accommodate current RWV models or the use of alternative scaffolds. Currently, immunofluorescence imaging of cytoskeletal and tight junctional markers represents an alternative method to evaluate model integrity. As these models grow in size and complexity, introduction of vasculature and nerve cells will be important. Finally, current models are not easily amenable to chronic infection due to lack of perfusion once removed from the RWV; however, inclusion of automated waste removal and nutrient delivery during infection will facilitate this approach.

**3-D organoid models.** The term organoid (“organ-like”) has been used to describe a variety of 3-D models that resemble *in vivo* tissues. Historically, this included models engineered with different technologies using cell lines, stem cells, primary cells, or tissue explants either embedded in or cultured on top of ECM scaffolds that allow cells to self-assemble into 3-D structures (8, 12, 143, 145, 146, 169, 171, 221–229). Advances in stem cell biology led to a recent terminology shift to more specifically define organoids as 3-D models derived from stem cells, progenitor cells, or primary explants (222, 230–238). Here we focus on 3-D models cultured within a 3-D ECM that fit this definition. It is important to emphasize that current models are based on decades of work by pioneering cell biologists that laid the foundation for the current organoid field (reviewed in reference 12), representing an advancement and merging of old and new technologies to enable novel discoveries (12, 228, 239). Models cultivated using thick ECMs have deep roots in tissue engineering and cancer biology, in which they were applied to develop advanced models enabling the study of a variety of biological mechanisms, particularly with regard to understanding the interrelationship between tissue structure and function (12). This effort resulted in a critical mass of scientists who now recognize the importance of 3-D models for infection and are bringing elegant advances to the field but may not be fully aware of their historical context.

A range of different organoid models have been established, including small and large intestine (229, 230, 232, 234, 240–268), lung (269–274), stomach (275–282), breast (55, 283, 284), brain (285–287), liver (222, 288, 289), pancreas (222, 290, 291), gallbladder (292), eye (293), kidney (294), prostate (222, 295, 296) and reproductive tract (297, 298), among others. Relative to monolayers, these models more closely mimic endogenous tissues, including organization and spontaneous differentiation of multiple cell types into physiologically relevant 3-D structures (Fig. 1B, panel e), expression and localization of tight junctions, mucus production, polarity, gene expression, cell viability and proliferation, cytokine production, responses to antimicrobials, support of commensals, and susceptibility to infection (12, 55, 222, 226, 228–235, 237, 238, 240–266, 269–319).

To develop 3-D organoid models, stem cells or tissue explants containing stem cells are used. Biopsy specimens may be treated with a dissociation agent and/or mechanically disrupted prior to embedding into ECM. Stem cells isolated from biopsy specimens can be predifferentiated into progenitor cells and further differentiated into ECM-embedded organoids. Differentiation into committed cell types is enabled by stepwise supplementation and/or removal of signaling factors during culture (249, 251,

252, 254, 264, 275, 278, 303, 320–322). Purified ECM components and mixtures can be used, including Matrigel, a laminin-rich ECM isolated from chondrosarcomas (323, 324). Synthetic hydrogels help circumvent challenges associated with Matrigel, including batch-to-batch variation and potential carcinogenic issues connected with tumor-derived matrices (229).

**3-D intestinal organoids.** Sato et al. (249) and Ootani et al. (253) independently reported conditions enabling long-term *in vitro* culture of mouse intestinal crypts containing Lgr5<sup>+</sup> stem cells (as well as purified Lgr5<sup>+</sup> stem cells that generate villus/crypt-like structures [249]). These approaches used either Matrigel (249) or collagen (253) in combination with supplementation of Wnt agonist R-spondin 1. Sato et al. also included epidermal growth factor to enable crypt growth and noggin to facilitate passaging (249). These models displayed a polarized, multicellular epithelium (enterocytes, goblet cells, Paneth cells, and enteroendocrine cells) organized into a central lumen lined by villus/crypt-like structures (249, 253). Murine intestinal organoids developed from single Lgr5<sup>+</sup> stem cells also developed into these multicellular structures (249). Subsequently, additional factors were included to enable human colonoid culture (264).

The NIH Intestinal Stem Cell Consortium defined a standardized nomenclature to reflect model sources, approaches, and *in vitro* structures (325). Structures directly isolated include epithelial sheets, crypts, and organoids (crypts and surrounding mesenchymal elements) (325). Various structures produced *in vitro* from small intestine include enterospheres (rounded epithelial cyst-like structures), enteroids (formation of budding crypts from enterospheres), and induced intestinal organoids (multicellular clusters from induced embryonal or pluripotent stem cells, e.g., induced human intestinal organoids [iHIOs]) (325). Analogous colonic structures include colonospheres, colonoids, and colonic organoids (325). It is common to see terms used interchangeably, and the nomenclature will likely evolve as the field expands.

Model infection can be accomplished by (i) addition of pathogen directly to the media (basal side), (ii) microinjection into the lumen (Fig. 1B, panel b), (iii) shearing of models into fragments followed by pathogen addition, and (iv) complete disruption of 3-D models into flat monolayers followed by pathogen addition (230, 237). Consideration of the normal infection route is critical. Direct addition to the media is easiest; however, for pathogens that infect via the apical/luminal side, this represents a nonphysiological route of infection. Microinjection is technically challenging but preferable for pathogens that normally infect from the lumen. Due to challenges associated with microinjection, there is a growing tendency to mechanically dissociate organoids into smaller pieces or completely dissociate them into monolayers on Transwell inserts or plastic (237, 261, 281, 313, 314). This approach has been successful for a number of studies, including cultivation of norovirus (314), a major advance in the field. Use of Transwell inserts also facilitates TEER analysis and easier cytokine sampling from the apical side of the model.

When dissociating 3-D models prior to infection, it is important to note that this disconnects their form and function, similar to disrupting primary tissue into monolayers, and may render them less predictive for some (not all) phenotypes. In this approach, Transwell inserts are preferable over plastic, as the former display improved physiological relevance over conventional monolayers (326). Additional profiling should confirm the extent to which the dissociated model may have dedifferentiated and additional culture time may be required to reestablish polarity/barrier function. Key findings should be validated using intact organoids and microinjection to avoid artifacts. Additionally, since ECM-pathogen interactions are important for infection dynamics (61), infection surfaces should not contain ECM components not typically found in that location *in vivo* (e.g., lumen) if the pathogen would not normally encounter it.

A variety of pathogens have been studied using 3-D enteroid/colonoid/organoid models, including *Salmonella*, *C. difficile*, EHEC, EPEC, enterotoxigenic *E. coli* (ETEC), norovirus, rotavirus, enteroviruses, *Toxoplasma gondii*, and coronaviruses (230, 231,

233–235, 238, 240–245, 257–263, 266, 268, 307–319, 327). The first infection using iHIOs was performed using human rotavirus, which lacks robust *in vitro* culture systems (315). Both laboratory and clinical rotaviruses replicated in iHIOs and were detected in epithelial and mesenchymal cells (315). Crypt-derived enteroids also supported rotavirus replication and were used to assess antiviral efficacy against patient isolates (244, 266). Ettayebi et al. made a significant advance by the successful *in vitro* culture of human norovirus (HuNoV), known for its lack of a reproducible culture system (314). The authors initially cultured 3-D intestinal organoids and then dissociated them into monolayers on plastic or Transwell inserts (314). Successful viral replication was observed and only enterocytes were infected with HuNoVs, regardless of the strain or the intestinal region from which the model was derived. Additional viral models, including those using enteroviruses (e.g., CVB, echovirus 11, and enterovirus 71) have identified the cell-type-specific nature of these infections and the virus-specific nature of innate immune signaling in response to infection (327).

Enteroid models were also used to study *S. Typhimurium* and *E. coli*. Zhang et al. (240) and Wilson et al. (243) used crypt-derived enteroids to study *Salmonella* infection. *S. Typhimurium* successfully colonized the model (240, 243), and infection responses aligned well with *in vivo* observations, including disruption of tight junctions, inflammatory responses, and decreased stem cell numbers (240). Forbester et al. infected iHIOs with *S. Typhimurium* and observed physiological transcriptomic and cytokine profiles (257). Injection of *E. coli* O157:H7 into iHIOs containing neutrophils led to loss of actin, epithelial integrity disruption, induction of inflammatory cytokines, and neutrophil recruitment (Fig. 1B, panel h) (260). In contrast, commensal *E. coli* was retained within the lumen, with no loss of model integrity. Infection of colonoid-derived Transwell models identified MUC2 and protocadherin-24 as early EHEC infection targets (261). Colonoids were initially cultured in 3-D, followed by dissociation onto Transwells. Model differentiation correlated with expression of differentiation markers, increased TEER, and microvilli (261). EHEC preferentially colonized the differentiated model relative to an undifferentiated control, reducing colonic mucus and inducing damage to microvilli. A similar approach was applied to study EPEC and ETEC infections in coculture models containing macrophages (313). Inclusion of macrophages in the bottom chamber of the enteroid-derived Transwell model enhanced barrier function, increased epithelial height, and altered cytokine responses relative to the control. EPEC increased total macrophage numbers and induced projections that extended into the epithelium, while ETEC induced macrophage extensions across the epithelium to the apical surface. The presence of macrophages in the coculture model enhanced barrier function and correlated with decreased numbers of ETEC organisms relative to the model lacking immune cells.

iHIOs were also used to study *C. difficile* infection (CDI) (258, 259, 262, 263). CDI patients secrete acidic mucus consisting primarily of MUC1, with decreased MUC2 and altered oligosaccharide composition relative to that in healthy patients (259). Injection of the pathogen alone into iHIOs decreased MUC2, while whole CDI stool supernatant was required to induce patient-like oligosaccharide composition changes (259). iHIOs were also used to investigate nontoxigenic and toxigenic strains of *C. difficile* and purified toxins TcdA and TcdB (262). Injection of the toxigenic isolate or purified TcdA led to a loss of barrier function, while iHIOs injected with the nontoxigenic strain remained intact. Separately, colonoids helped identify Frizzled proteins as receptors for the TcdB toxin (263).

In summary, 3-D organoid models are advancing mechanistic understanding of host-microbe interactions due to their enhanced 3-D architecture and presence of Lgr5<sup>+</sup> stem cells together with multiple cell types and other functional properties. In addition, patient organoid “biobanks” have been established and are facilitating fundamental research and clinical applications (230, 231, 328, 329). One exciting example of the applicability of these models is the use of patient-derived organoids to predict drug responses for cystic fibrosis treatment (222, 231, 250, 307, 329, 330).

**Limitations and future directions of 3-D organoids.** As for other models, organoids have limitations that researchers are working to overcome. Variability and quality control challenges between experimental preparations includes (i) heterogeneity in size, shape, and viability of organoids within a culture and across different samples, (ii) batch-to-batch variability in Matrigel or other ECM, and (iii) batch-to-batch variability in growth factor sources. Organoid infection presents challenges as described above. Medium cost is high if scaling up due to reliance on specific growth factors. Incorporation of the full array of cell types found *in vivo*, including the diverse collection of immune cells and microbiota, has not been attained. Organoid models also lack spontaneous M cell formation (251, 331). Pretreatment of *in vitro* models with RANKL, exposure to lymphocytes, or infection with pathogens like *S. Typhimurium* can induce M cell formation (331–333). Although the mechanism by which M cells spontaneously differentiate in RWV models (11, 152, 171, 175) is unknown, it is possible that the low-fluid-shear suspension culture environment is important, since flotation of ECM scaffolds was more permissive for differentiation than surface-attached ECM (12, 155, 156). Since organoid models are typically ECM embedded, another limitation is that the application of the range of biomechanical forces found *in vivo* is limited; however, an iHIO model containing functional neurons that enabled peristalsis-like contractions was reported (256). Combinations of technologies, including organoid-derived 3-D models developed using the RWV bioreactor (202) and organ-on-a-chip (OAC) (334), are further expanding these capabilities. TEER measurements are also not currently possible with intact organoid models due to their size and structure and because they are ECM embedded. Some studies have dissociated organoids into 2-D on Transwells to facilitate these measurements, although there can be disadvantages to using this approach, as discussed.

**Organ-on-a-chip models.** Advanced microfluidic and microfabrication technologies are being broadly applied to develop organ-on-a-chip models that mimic key aspects of *in vivo* microenvironments. Rather than focusing on recreating the 3-D structure of the entire tissue, this technology aims to recreate a microscale model of the local 3-D architecture and spatial distribution of dynamic tissue interfaces to mimic tissue- and organ-level functions (335). These devices are designed with micrometer-sized fluidic channels separated by thin, flexible porous membranes that enable development of different tissues in adjacent chambers while retaining their ability to interact (Fig. 1B, panel c) (335–339). These features allow flexibility to model active processes within a tissue, such as vascular-like perfusion. One exciting functional feature engineered into the design of many of these devices is the capability to apply dynamic forces across the tissue to model fluid shear and peristalsis (334, 340–343).

OAC models vary in complexity, ranging from simple systems containing a single perfused chamber and cell type to more advanced chips that contain several microchannels, membranes, and assorted cell types, thereby allowing the reconstruction of multiple tissue interfaces (335). Microengineering techniques for these devices have been extensively reviewed (335, 338, 344–349). Chips are commonly made of a silicone polymer called polydimethylsiloxane (PDMS), which is compatible with many cell types and has several advantages, including optical transparency for easy imaging, low cost, flexibility, and high gas permeability (335, 339, 344, 350). PDMS does carry some disadvantages (discussed below), so other options are being explored (350, 351). Depending on experimental requirements, chip design and approaches for tissue development can be altered. Porous membranes can be coated with a variety of matrices/scaffolds (335, 339, 344, 345, 352). Moreover, 3-D bioprinting techniques are facilitating complex spatial patterning of cells and scaffolds (352). Although traditional electrodes used for TEER measurements do not accommodate the small culture area of most OAC models (220), recent studies have integrated custom electrodes (353).

A variety of OAC platforms have been derived from cell lines, stem cells, and/or primary cells, including small and large intestine (334, 340–342, 353–356), lung (357–361), liver (362–369), kidney (370–372), heart (373–377), cornea (378), skin (379),

nervous tissue (380–383), bone (384, 385), reproductive tract (386), and blood/endothelium and blood-brain barrier (387–393), among others. Once developed, these models typically retain their structural and functional integrity for several weeks (model specific), further lending to their experimental tractability. Similar to the other 3-D models discussed, OAC models exhibit *in vivo*-like characteristics, including spontaneous differentiation into multiple cell types, polarity/barrier function, formation of local 3-D structures (Fig. 1B, panel f), responses to biophysical forces, cytokine production, gene expression, mucus production, responses to nanoparticles and drugs, support of commensals, responses to microbial components (e.g., LPS), and/or susceptibility to microbial infections (334, 335, 339–342, 354–377, 379–394). The application of physical forces across several of these models alters physiological responses, including changes in expression/localization of tight junctions, barrier integrity/function, polarity and differentiation, cell viability, size, morphology, ECM production, integrin expression, enzyme activity, cytokine responses, chemical/gas exchange gradients, molecular transport, drug responses, bacterial colonization, virion-related cytopathic effects, and/or formation of 3-D structures (e.g., villi) (334, 340–343, 345, 358, 359, 361, 371, 372, 376, 377, 384, 387, 388, 395). Importantly, several models have been advanced to incorporate immune cells (342, 359, 396). Below we discuss examples of gut-on-a-chip models that have been applied to study pathogens or commensals.

**Gut-on-a-chip models.** The Ingber laboratory developed a series of “mechanically active” gut-on-a-chip models and applied them to study host-microbe interactions (340, 342, 343). They initially constructed a PDMS chip containing two microfluidic channels separated by a flexible, porous ECM-coated membrane (340). Colonic cells were seeded in the upper channel under low-fluid-shear stress (0.006 to 0.06 dyne/cm<sup>2</sup>), and medium also flowed in the bottom chamber. The chip was engineered with dual vacuum chambers on either side of the main microchamber to enable application of a physiological cyclic strain across the membrane to mimic intestinal peristalsis. This led to a highly polarized columnar epithelium and spontaneous formation of 3-D villus-like folds with basal proliferative cells in the crypt region. Model characterization revealed well-formed tight junctions, mucus production, and multiple intestinal epithelial cell types (absorptive, goblet, enteroendocrine, and Paneth cells) (340, 341). The ability of this model to support commensal colonization was assessed using *Lactobacillus rhamnosus* LGG. Colonization of LGG improved barrier function and was supported for greater than a week without impacting model integrity, consistent with previous *in vivo* observations for probiotics. The model was also applied to study host-virus interactions using CVB (Fig. 1B, panel i) (343). Exposure of CVB to the apical surface led to successful viral replication, induction of cytopathic effects (CPE), and polarized (apical) release of proinflammatory cytokines. Infection of the basal side led to decreased viral titers and lower CPE, with apical secretion of proinflammatory cytokines.

The above-described gut-on-a-chip model was further advanced to include immune cells (peripheral blood mononuclear cells [PBMCs]) and/or endothelial cells (vascular or lymphatic) (342). This combination of models enabled exploration of the interplay between these factors (and others) in bacterial overgrowth and inflammation in the onset of intestinal injury. Synergistic effects between PBMCs and either nonpathogenic *E. coli*, pathogenic enteroinvasive *E. coli* (EIEC), or purified lipopolysaccharide (LPS) led to altered barrier function and changes in villus architecture. Similarly, the presence of both PBMCs and LPS led to polarized secretion of basal proinflammatory cytokines, which stimulates recruitment of additional immune cells in an *in vivo* scenario. Exposure of the PBMC-containing model to a therapeutic formulation of probiotic bacteria increased barrier function. The formulation reduced EIEC-induced intestinal damage in the model lacking PBMCs but in the presence of immune cells only delayed injury onset. Cessation of cyclic stretching led to enhanced bacterial overgrowth, even under constant medium flow.

**Limitations and future directions of OAC models.** While there are many advantages to OAC models, there are limitations. Many of these models have multiple cell types which exhibit enhanced 3-D architecture; however, the vast array of native heterogeneous cell types found *in vivo* still need to be incorporated and different laboratories are optimizing ECM composition and structure. Along these lines, to our knowledge, no one has yet reported the presence of M cells in gut-on-a-chip models. There is also a strong push for physically linked multiorgan models, or “humans-on-chips” (338, 397). Another limitation is the PDMS material commonly used for chip construction, which can absorb small hydrophobic molecules and interfere with drug screening and cell signaling analysis (338, 350, 351). There are also risks of uncross-linked PDMS leaching into the culture if the curing process is incomplete, causing cell damage (350, 351). While the small number of cells required can be considered advantageous, in some cases, larger numbers of cells (106, 107) may be required depending on the experiment. Infection studies typically involve many permutations, and it is not uncommon to use several multiwell plates within a single experiment. For example, during colonization assays, samples are harvested at different times and plated for viable bacteria, while others are processed for downstream analyses. Thus, it will be beneficial to incorporate multiple 3-D model systems into infectious disease research depending on the experimental question being addressed, as no single model system is sufficient to address all infectious disease experimental scenarios.

## CONCLUSIONS

Over the past 2 decades, a multidisciplinary consortium of researchers has been creative in developing 3-D intestinal models of increasing complexity that better mimic the biological, chemical, and physical microenvironments of the endogenous tissue for studying host-microbe interactions. These models have been developed using a variety of approaches and are being applied to understand the dynamic relationship between the host, pathogens, and commensals that dictate infection outcome and for development of new treatment/prevention strategies. Collectively, these models have ushered in a new era for infectious disease research by offering predictive *in vitro* translational platforms. Indeed, the establishment of 3-D intestinal models and their application as human surrogates for infectious disease research have provided specific examples of how the study of microbial pathogenesis can be advanced by using appropriate, biologically meaningful models.

We are still in the infancy of learning how to build more realistic 3-D tissue models, and there remain an endless number of questions and hypotheses to test about how infection actually happens in the body. Continued model advancement to better recapitulate the *in vivo* tissue microenvironment coupled with the application of multiple 3-D model systems will lead to increased translation of research discoveries to practical and significant outcomes. Such advances will be pivotal for the success of personalized medicine approaches using patient-specific normal and diseased cells and of incorporation of the full repertoire of immune cells to predict clinical correlates of protection for vaccine development.

Toward this goal, we must deeply comprehend 3-D tissue/organ structure and function, the associated microenvironment, and the microorganisms to be studied. It is likewise important that we are aware of and acknowledge the rich history and work of researchers who have long applied 3-D tissue modeling to study host-pathogen interactions. Accordingly, we should revisit past research in the field to help us understand and guide our direction. While it remains a daunting task to gain a complete understanding of infectious disease, the alignment of multidisciplinary research teams dedicated to the establishment of 3-D models that reconstruct the architecture and function of the *in vivo* organ and their application for host-pathogen interaction studies make this an exciting time to be a scientist!

## ACKNOWLEDGMENTS

We thank Michael Northrop for his illustration in Fig. 1. We apologize to authors whose work we were unable to cite due to length limitations given the extensive literature available for each model system.

This work was funded by NASA grants NNX13AM01G and NNX15AL06G (C.A.N., J.B., and C.M.O.) and NIH R01-AI081759 (C.B.C. and C.A.N.).

## REFERENCES

- Nickerson C, Ott CM, Wilson JW, Pierson DL. 2004. Microbial responses to microgravity and other low shear environment. *Microbiol Mol Biol Rev* 68:345–361. <https://doi.org/10.1128/MMBR.68.2.345-361.2004>.
- Persat A. 2017. Bacterial mechanotransduction. *Curr Opin Microbiol* 36:1–6. <https://doi.org/10.1016/j.mib.2016.12.002>.
- Persat A, Nadell CD, Kim MK, Ingremeau F, Siryaporn A, Drescher K, Wingreen NS, Bassler BL, Gitai Z, Stone HA. 2015. The mechanical world of bacteria. *Cell* 161:988–997. <https://doi.org/10.1016/j.cell.2015.05.005>.
- Thomas WE, Trintchina E, Forero M, Vogel V, Sokurenko EV. 2002. Bacterial adhesion to target cells enhanced by shear force. *Cell* 109:913–923. [https://doi.org/10.1016/S0092-8674\(02\)00796-1](https://doi.org/10.1016/S0092-8674(02)00796-1).
- Alsharif G, Ahmad S, Islam MS, Shah R, Busby SJ, Krachler AM. 2015. Host attachment and fluid shear are integrated into a mechanical signal regulating virulence in *Escherichia coli* O157:H7. *Proc Natl Acad Sci U S A* 112:5503–5508. <https://doi.org/10.1073/pnas.1422986112>.
- Fang FC, Frawley ER, Tapscott T, Vazquez-Torres A. 2016. Bacterial stress responses during host infection. *Cell Host Microbe* 20:133–143. <https://doi.org/10.1016/j.chom.2016.07.009>.
- McGuckin MA, Linden SK, Sutton P, Florin TH. 2011. Mucin dynamics and enteric pathogens. *Nat Rev Microbiol* 9:265–278. <https://doi.org/10.1038/nrmicro2538>.
- Barrila J, Radtke AL, Crabbe A, Sarker SF, Herbst-Kralovetz MM, Ott CM, Nickerson CA. 2010. Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. *Nat Rev Microbiol* 8:791–801. <https://doi.org/10.1038/nrmicro2423>.
- Ibarra JA, Steele-Mortimer O. 2009. Salmonella—the ultimate insider. Salmonella virulence factors that modulate intracellular survival. *Cell Microbiol* 11:1579–1586. <https://doi.org/10.1111/j.1462-5822.2009.01368.x>.
- Costello CM, Sorna RM, Goh YL, Cengic I, Jain NK, March JC. 2014. 3-D intestinal scaffolds for evaluating the therapeutic potential of probiotics. *Mol Pharm* 11:2030–2039. <https://doi.org/10.1021/mp5001422>.
- Nickerson CA, Goodwin TJ, Terlonge J, Ott CM, Buchanan KL, Uicker WC, Emami K, LeBlanc CL, Ramamurthy R, Clarke MS, Vanderburg CR, Hammond T, Pierson DL. 2001. Three-dimensional tissue assemblies: novel models for the study of *Salmonella enterica* serovar Typhimurium pathogenesis. *Infect Immun* 69:7106–7120. <https://doi.org/10.1128/IAI.69.11.7106-7120.2001>.
- Simian M, Bissell MJ. 2017. Organoids: a historical perspective of thinking in three dimensions. *J Cell Biol* 216:31–40. <https://doi.org/10.1083/jcb.201610056>.
- Bissell MJ. 1981. The differentiated state of normal and malignant cells or how to define a “normal” cell in culture. *Int Rev Cytol* 70:27–100.
- Schwarz RI, Bissell MJ. 1977. Dependence of the differentiated state on the cellular environment: modulation of collagen synthesis in tendon cells. *Proc Natl Acad Sci U S A* 74:4453–4457.
- Griffith LG, Swartz MA. 2006. Capturing complex 3D tissue physiology in vitro. *Nat Rev Mol Cell Biol* 7:211–224. <https://doi.org/10.1038/nrm1858>.
- Yamada KM, Cukierman E. 2007. Modeling tissue morphogenesis and cancer in 3D. *Cell* 130:601–610. <https://doi.org/10.1016/j.cell.2007.08.006>.
- Bissell MJ, Aggeler J. 1987. Dynamic reciprocity: how do extracellular matrix and hormones direct gene expression? *Prog Clin Biol Res* 249:251–262.
- Jorgens DM, Inman JL, Wojcik M, Robertson C, Palsdottir H, Tsai WT, Huang H, Bruni-Cardoso A, Lopez CS, Bissell MJ, Xu K, Auer M. 2017. Deep nuclear invaginations are linked to cytoskeletal filaments—integrated bioimaging of epithelial cells in 3D culture. *J Cell Sci* 130:177–189. <https://doi.org/10.1242/jcs.190967>.
- Maniotis AJ, Chen CS, Ingber DE. 1997. Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure. *Proc Natl Acad Sci U S A* 94:849–854.
- Bissell MJ, Hall HG, Parry G. 1982. How does the extracellular matrix direct gene expression? *J Theor Biol* 99:31–68. [https://doi.org/10.1016/0022-5193\(82\)90388-5](https://doi.org/10.1016/0022-5193(82)90388-5).
- Boudreau N, Myers C, Bissell MJ. 1995. From laminin to lamin: regulation of tissue-specific gene expression by the ECM. *Trends Cell Biol* 5:1–4. [https://doi.org/10.1016/S0962-8924\(00\)88924-2](https://doi.org/10.1016/S0962-8924(00)88924-2).
- Tapley EC, Starr DA. 2013. Connecting the nucleus to the cytoskeleton by SUN-KASH bridges across the nuclear envelope. *Curr Opin Cell Biol* 25:57–62. <https://doi.org/10.1016/j.ceb.2012.10.014>.
- Xu R, Spencer VA, Groesser DL, Bissell MJ. 2010. Laminin regulates PI3K basal localization and activation to sustain STAT5 activation. *Cell Cycle* 9:4315–4322. <https://doi.org/10.4161/cc.9.21.13578>.
- Kim DH, Wirtz D. 2015. Cytoskeletal tension induces the polarized architecture of the nucleus. *Biomaterials* 48:161–172. <https://doi.org/10.1016/j.biomaterials.2015.01.023>.
- Hagios C, Lochter A, Bissell MJ. 1998. Tissue architecture: the ultimate regulator of epithelial function? *Philos Trans R Soc Lond B Biol Sci* 353:857–870. <https://doi.org/10.1098/rstb.1998.0250>.
- Doyle AD, Yamada KM. 2016. Mechanosensing via cell-matrix adhesions in 3D microenvironments. *Exp Cell Res* 343:60–66. <https://doi.org/10.1016/j.yexcr.2015.10.033>.
- Ingber DE. 2003. Tensegrity I. Cell structure and hierarchical systems biology. *J Cell Sci* 116:1157–1173. <https://doi.org/10.1242/jcs.00359>.
- Ingber DE. 2003. Mechanobiology and diseases of mechanotransduction. *Ann Med* 35:564–577. <https://doi.org/10.1080/07853890310016333>.
- Ingber DE. 2003. Tensegrity II. How structural networks influence cellular information processing networks. *J Cell Sci* 116:1397–1408. <https://doi.org/10.1242/jcs.00360>.
- Ingber DE. 2008. Tensegrity-based mechanosensing from macro to micro. *Prog Biophys Mol Biol* 97:163–179. <https://doi.org/10.1016/j.pbiomolbio.2008.02.005>.
- Ingber DE. 2006. Cellular mechanotransduction: putting all the pieces together again. *FASEB J* 20:811–827. <https://doi.org/10.1096/fj.05-5424rev>.
- Gruenheid S, Finlay BB. 2003. Microbial pathogenesis and cytoskeletal function. *Nature* 422:775–781. <https://doi.org/10.1038/nature01603>.
- Taylor MP, Koyuncu OO, Enquist LW. 2011. Subversion of the actin cytoskeleton during viral infection. *Nat Rev Microbiol* 9:427–439. <https://doi.org/10.1038/nrmicro2574>.
- Delorme-Axford E, Coyne CB. 2011. The actin cytoskeleton as a barrier to virus infection of polarized epithelial cells. *Viruses* 3:2462. <https://doi.org/10.3390/v3122462>.
- Nickerson CA, Ott CM, Mister SJ, Morrow BJ, Burns-Keliher L, Pierson DL. 2000. Microgravity as a novel environmental signal affecting *Salmonella enterica* serovar Typhimurium virulence. *Infect Immun* 68:3147–3152. <https://doi.org/10.1128/IAI.68.6.3147-3152.2000>.
- Wilson JW, Ott CM, Ramamurthy R, Porwollik S, McClelland M, Pierson DL, Nickerson CA. 2002. Low-shear modeled microgravity alters the *Salmonella enterica* serovar Typhimurium stress response in an RpoS-independent manner. *Appl Environ Microbiol* 68:5408–5416. <https://doi.org/10.1128/AEM.68.11.5408-5416.2002>.
- Wilson JW, Ramamurthy R, Porwollik S, McClelland M, Hammond T, Allen P, Ott CM, Pierson DL, Nickerson CA. 2002. Microarray analysis identifies *Salmonella* genes belonging to the low-shear modeled microgravity regulon. *Proc Natl Acad Sci U S A* 99:13807–13812. <https://doi.org/10.1073/pnas.212387899>.
- Nauman EA, Ott CM, Sander E, Tucker DL, Pierson D, Wilson JW, Nickerson CA. 2007. Novel quantitative biosystem for modeling phys-



- iological fluid shear stress on cells. *Appl Environ Microbiol* 73:699–705. <https://doi.org/10.1128/AEM.02428-06>.
39. Crabbé A, De Boever P, Van Houdt R, Moors H, Mergeay M, Cornelis P. 2008. Use of the rotating wall vessel technology to study the effect of shear stress on growth behaviour of *Pseudomonas aeruginosa* PA01. *Environ Microbiol* 10:2098–2110. <https://doi.org/10.1111/j.1462-2920.2008.01631.x>.
  40. Crabbé A, Pycke B, Van Houdt R, Monsieurs P, Nickerson C, Leys N, Cornelis P. 2010. Response of *Pseudomonas aeruginosa* PA01 to low shear modelled microgravity involves AlgU regulation. *Environ Microbiol* 12:1545–1564. <https://doi.org/10.1111/j.1462-2920.2010.02184.x>.
  41. Pacello F, Rotilio G, Battistoni A. 2012. Low-shear modeled microgravity enhances *Salmonella enterica* resistance to hydrogen peroxide through a mechanism involving KatG and KatN. *Open Microbiol J* 6:53–64. <https://doi.org/10.2174/1874285801206010053>.
  42. Aprikian RR, Interlandi G, Kidd BA, Le Trong I, Tchesnokova V, Yakovenko O, Whitfield MJ, Bullitt E, Stenkamp RE, Thomas WE, Sokurenko EV. 2011. The bacterial fimbrial tip acts as a mechanical force sensor. *PLoS Biol* 9:e1000617. <https://doi.org/10.1371/journal.pbio.1000617>.
  43. Isberg RR, Barnes P. 2002. Dancing with the host; flow-dependent bacterial adhesion. *Cell* 110:1–4. [https://doi.org/10.1016/S0092-8674\(02\)00821-8](https://doi.org/10.1016/S0092-8674(02)00821-8).
  44. Persat A, Inclan YF, Engel JN, Stone HA, Gitai Z. 2015. Type IV pili mechanochemically regulate virulence factors in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 112:7563–7568. <https://doi.org/10.1073/pnas.1502025112>.
  45. Yang J, Barrila J, Roland KL, Ott CM, Nickerson CA. 2016. Physiological fluid shear alters the virulence potential of invasive multidrug-resistant non-typhoidal *Salmonella* Typhimurium D23580. *NPJ Microgravity* 2:16021. <https://doi.org/10.1038/npmjgrav.2016.21>.
  46. Dingemans J, Monsieurs P, Yu SH, Crabbé A, Forstner KU, Malfroot A, Cornelis P, Van Houdt R. 2016. Effect of shear stress on *Pseudomonas aeruginosa* isolated from the cystic fibrosis lung. *mBio* 7:e00813-16. <https://doi.org/10.1128/mBio.00813-16>.
  47. Castro SL, Nelman-Gonzalez M, Nickerson CA, Ott CM. 2011. Induction of attachment-independent biofilm formation and repression of Hfq expression by low-fluid-shear culture of *Staphylococcus aureus*. *Appl Environ Microbiol* 77:6368–6378. <https://doi.org/10.1128/AEM.00175-11>.
  48. Tarbell JM, Weinbaum S, Kamm RD. 2005. Cellular fluid mechanics and mechanotransduction. *Ann Biomed Eng* 33:1719–1723. <https://doi.org/10.1007/s10439-005-8775-z>.
  49. Kaul H, Ventikos Y. 2015. Dynamic reciprocity revisited. *J Theor Biol* 370:205–208. <https://doi.org/10.1016/j.jtbi.2015.01.016>.
  50. Rutkowski JM, Swartz MA. 2007. A driving force for change: interstitial flow as a morphoregulator. *Trends Cell Biol* 17:44–50. <https://doi.org/10.1016/j.tcb.2006.11.007>.
  51. Long JP, Pierson SS, Hughes JH. 1998. Rhinovirus replication in HeLa cells cultured under conditions of simulated microgravity. *Aviat Space Environ Med* 69:851–856.
  52. Bissell MJ, Rizki A, Mian IS. 2003. Tissue architecture: the ultimate regulator of breast epithelial function. *Curr Opin Cell Biol* 15:753–762. <https://doi.org/10.1016/j.ccb.2003.10.016>.
  53. Correia AL, Bissell MJ. 2012. The tumor microenvironment is a dominant force in multidrug resistance. *Drug Resist Updat* 15:39–49. <https://doi.org/10.1016/j.drug.2012.01.006>.
  54. Nelson CM, Bissell MJ. 2006. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. *Annu Rev Cell Dev Biol* 22:287–309. <https://doi.org/10.1146/annurev.cellbio.22.010305.104315>.
  55. Schmeichel KL, Bissell MJ. 2003. Modeling tissue-specific signaling and organ function in three dimensions. *J Cell Sci* 116:2377–2388. <https://doi.org/10.1242/jcs.00503>.
  56. Bals R, Hiemstra PS. 2004. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. *Eur Respir J* 23:327–333. <https://doi.org/10.1183/09031936.03.00098803>.
  57. Crabbé A, Ledesma MA, Nickerson CA. 2014. Mimicking the host and its microenvironment in vitro for studying mucosal infections by *Pseudomonas aeruginosa*. *Pathog Dis* 71:1–19. <https://doi.org/10.1111/2049-632X.12180>.
  58. Duerkop BA, Vaishnav S, Hooper LV. 2009. Immune responses to the microbiota at the intestinal mucosal surface. *Immunity* 31:368–376. <https://doi.org/10.1016/j.immuni.2009.08.009>.
  59. Kraehenbuhl J-P, Corbett M. 2004. Keeping the gut microflora at bay. *Science* 303:1624–1625. <https://doi.org/10.1126/science.1096222>.
  60. Lopetuso LR, Scaldaferrri F, Franceschi F, Gasbarrini A. 2014. The gastrointestinal microbiome—functional interference between stomach and intestine. *Best Pract Res Clin Gastroenterol* 28:995–1002. <https://doi.org/10.1016/j.bpg.2014.10.004>.
  61. Singh B, Fleury C, Jalalvand F, Riesbeck K. 2012. Human pathogens utilize host extracellular matrix proteins laminin and collagen for adhesion and invasion of the host. *FEMS Microbiol Rev* 36:1122–1180. <https://doi.org/10.1111/j.1574-6976.2012.00340.x>.
  62. Allen CA, Niesel DW, Torres AG. 2008. The effects of low-shear stress on adherent-invasive *Escherichia coli*. *Environ Microbiol* 10:1512–1525. <https://doi.org/10.1111/j.1462-2920.2008.01567.x>.
  63. Fonseca AP, Sousa JC. 2007. Effect of shear stress on growth, adhesion and biofilm formation of *Pseudomonas aeruginosa* with antibiotic-induced morphological changes. *Int J Antimicrob Agents* 30:236–241. <https://doi.org/10.1016/j.ijantimicag.2007.04.011>.
  64. Lynch SV, Mukundakrishnan K, Benoit MR, Ayyaswamy PS, Matin A. 2006. *Escherichia coli* biofilms formed under low-shear modeled microgravity in a ground-based system. *Appl Environ Microbiol* 72:7701–7710. <https://doi.org/10.1128/AEM.01294-06>.
  65. Mestecky J, Strober W, Russell MW, Kelsall BL, Chouhrouh H, Lambrecht BN. 2015. *Mucosal immunology*. Elsevier, San Diego, CA.
  66. Gerbe F, Legraverend C, Jay P. 2012. The intestinal epithelium tuft cells: specification and function. *Cell Mol Life Sci* 69:2907–2917. <https://doi.org/10.1007/s00018-012-0984-7>.
  67. Peterson LW, Artis D. 2014. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat Rev Immunol* 14:141–153. <https://doi.org/10.1038/nri3608>.
  68. Mowat AM, Agace WW. 2014. Regional specialization within the intestinal immune system. *Nat Rev Immunol* 14:667–685. <https://doi.org/10.1038/nri3738>.
  69. Cerutti A. 2008. The regulation of IgA class switching. *Nat Rev Immunol* 8:421–434. <https://doi.org/10.1038/nri2322>.
  70. Cerutti A, Rescigno M. 2008. The biology of intestinal immunoglobulin A responses. *Immunity* 28:740–750. <https://doi.org/10.1016/j.immuni.2008.05.001>.
  71. Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. *Nat Med* 11:S45–S53. <https://doi.org/10.1038/nm1213>.
  72. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. 2008. The immune geography of IgA induction and function. *Mucosal Immunol* 1:11–22. <https://doi.org/10.1038/mi.2007.6>.
  73. Engel J, Eran Y. 2011. Subversion of mucosal barrier polarity by *Pseudomonas aeruginosa*. *Front Microbiol* 2:114. <https://doi.org/10.3389/fmicb.2011.00114>.
  74. Zihni C, Balda MS, Matter K. 2014. Signalling at tight junctions during epithelial differentiation and microbial pathogenesis. *J Cell Sci* 127:3401–3413. <https://doi.org/10.1242/jcs.145029>.
  75. Schneeberger K, Roth S, Nieuwenhuis EES, Middendorp S. 2018. Intestinal epithelial cell polarity defects in disease: lessons from microvillus inclusion disease. *Dis Model Mech* 11:dmm031088. <https://doi.org/10.1242/dmm.031088>.
  76. Jung C, Hugot JP, Barreau F. 2010. Peyer's patches: the immune sensors of the intestine. *Int J Inflam* 2010:823710. <https://doi.org/10.4061/2010/823710>.
  77. Cohen CJ, Shieh JTC, Pickles RJ, Okegawa T, Hsieh J-T, Bergelson JM. 2001. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. *Proc Natl Acad Sci U S A* 98:15191–15196. <https://doi.org/10.1073/pnas.261452898>.
  78. Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, Schnell FJ, Nusrat A, Parkos CA, Dermody TS. 2001. Junction adhesion molecule is a receptor for reovirus. *Cell* 104:441–451. [https://doi.org/10.1016/S0092-8674\(01\)00231-8](https://doi.org/10.1016/S0092-8674(01)00231-8).
  79. Bonazzi M, Cossart P. 2011. Impenetrable barriers or entry portals? The role of cell-cell adhesion during infection. *J Cell Biol* 195:349–358. <https://doi.org/10.1083/jcb.201106011>.
  80. Höner zu Bentrup K, Ramamurthy R, Ott CM, Emami K, Nelman-Gonzalez M, Wilson JW, Richter EG, Goodwin TJ, Alexander JS, Pierson DL, Pellis N, Buchanan KL, Nickerson CA. 2006. Three-dimensional organotypic models of human colonic epithelium to study the early stages of enteric salmonellosis. *Microbes Infect* 8:1813–1825. <https://doi.org/10.1016/j.micinf.2006.02.020>.
  81. Fleiszig SM, Evans DJ, Do N, Vallas V, Shin S, Mostov KE. 1997. Epithelial cell polarity affects susceptibility to *Pseudomonas aeruginosa* invasion and cytotoxicity. *Infect Immun* 65:2861–2867.
  82. Hurley BP, McCormick BA. 2003. Translating tissue culture results into

- animal models: the case of *Salmonella typhimurium*. *Trends Microbiol* 11:562–569. <https://doi.org/10.1016/j.tim.2003.10.002>.
83. Law RJ, Gur-Arie L, Rosenshine I, Finlay BB. 2013. In vitro and in vivo model systems for studying enteropathogenic *Escherichia coli* infections. *Cold Spring Harb Perspect Med* 3:a009977. <https://doi.org/10.1101/cshperspect.a009977>.
  84. Ashida H, Ogawa M, Kim M, Mimuro H, Sasakawa C. 2011. Bacteria and host interactions in the gut epithelial barrier. *Nat Chem Biol* 8:36–45. <https://doi.org/10.1038/nchembio.741>.
  85. Clemente JC, Ursell LK, Parfrey LW, Knight R. 2012. The impact of the gut microbiota on human health: an integrative view. *Cell* 148:1258–1270. <https://doi.org/10.1016/j.cell.2012.01.035>.
  86. Krishnan S, Alden N, Lee K. 2015. Pathways and functions of gut microbiota metabolism impacting host physiology. *Curr Opin Biotechnol* 36:137–145. <https://doi.org/10.1016/j.copbio.2015.08.015>.
  87. Chu H, Mazmanian SK. 2013. Innate immune recognition of the microbiota promotes host-microbial symbiosis. *Nat Immunol* 14:668–675. <https://doi.org/10.1038/ni.2635>.
  88. Vaishnava S, Yamamoto M, Severson KM, Ruhn KA, Yu X, Koren O, Ley R, Wakeland EK, Hooper LV. 2011. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. *Science* 334:255–258. <https://doi.org/10.1126/science.1209791>.
  89. Maynard CL, Elson CO, Hatton RD, Weaver CT. 2012. Reciprocal interactions of the intestinal microbiota and immune system. *Nature* 489:231–241. <https://doi.org/10.1038/nature11551>.
  90. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. 2005. Diversity of the human intestinal microbial flora. *Science* 308:1635–1638. <https://doi.org/10.1126/science.1110591>.
  91. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. 2012. Diversity, stability and resilience of the human gut microbiota. *Nature* 489:220–230. <https://doi.org/10.1038/nature11550>.
  92. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. 2007. The human microbiome project. *Nature* 449:804–810. <https://doi.org/10.1038/nature06244>.
  93. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464:59–65. <https://doi.org/10.1038/nature08821>.
  94. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borrueal N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Dore J, MetaHIT Consortium, Antolin M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariac G, Deryn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, Mrini C, Muller J, Zozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. 2011. Enterotypes of the human gut microbiome. *Nature* 473:174–180. <https://doi.org/10.1038/nature09944>.
  95. Donaldson GP, Lee SM, Mazmanian SK. 2016. Gut biogeography of the bacterial microbiota. *Nat Rev Microbiol* 14:20–32. <https://doi.org/10.1038/nrmicro3552>.
  96. Lavelle A, Lennon G, O'Sullivan O, Docherty N, Balfe A, Maguire A, Mulcahy HE, Doherty G, O'Donoghue D, Hyland J, Ross RP, Coffey JC, Sheahan K, Cotter PD, Shanahan F, Winter DC, O'Connell PR. 2015. Spatial variation of the colonic microbiota in patients with ulcerative colitis and control volunteers. *Gut* 64:1553–1561. <https://doi.org/10.1136/gutjnl-2014-307873>.
  97. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. 2016. The gut microbiota and host health: a new clinical frontier. *Gut* 65:330–339. <https://doi.org/10.1136/gutjnl-2015-309990>.
  98. Lynch SV, Pedersen O. 2016. The human intestinal microbiome in health and disease. *N Engl J Med* 375:2369–2379. <https://doi.org/10.1056/NEJMra1600266>.
  99. Kassam Z, Lee CH, Yuan Y, Hunt RH. 2013. Fecal microbiota transplantation for *Clostridium difficile* infection: systematic review and meta-analysis. *Am J Gastroenterol* 108:500–508. <https://doi.org/10.1038/ajg.2013.59>.
  100. Gianotti RJ, Moss AC. 2017. Fecal microbiota transplantation: from *Clostridium difficile* to inflammatory bowel disease. *Gastroenterol Hepatol (N Y)* 13:209–213.
  101. Parker D, Prince A. 2011. Innate immunity in the respiratory epithelium. *Am J Respir Cell Mol Biol* 45:189–201. <https://doi.org/10.1165/rcmb.2011-0011RT>.
  102. Johansson ME, Ambort D, Pelaseyed T, Schutte A, Gustafsson JK, Ermund A, Subramani DB, Holmen-Larsson JM, Thomsson KA, Bergstrom JH, van der Post S, Rodriguez-Pineiro AM, Sjovall H, Backstrom M, Hansson GC. 2011. Composition and functional role of the mucus layers in the intestine. *Cell Mol Life Sci* 68:3635–3641. <https://doi.org/10.1007/s00018-011-0822-3>.
  103. Johansson ME, Larsson JM, Hansson GC. 2011. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proc Natl Acad Sci U S A* 108(Suppl 1):S4659–S4665. <https://doi.org/10.1073/pnas.1006451107>.
  104. Li H, Limenitakis JP, Fuhrer T, Geuking MB, Lawson MA, Wyss M, Brugiroux S, Keller I, Macpherson JA, Rupp S, Stolp B, Stein JV, Stecher B, Sauer U, McCoy KD, Macpherson AJ. 2015. The outer mucus layer hosts a distinct intestinal microbial niche. *Nat Commun* 6:8292. <https://doi.org/10.1038/ncomms9292>.
  105. Rogier EW, Frantz AL, Bruno MEC, Kaetzel CS. 2014. Secretory IgA is concentrated in the outer layer of colonic mucus along with gut bacteria. *Pathogens* 3:390–403. <https://doi.org/10.3390/pathogens3020390>.
  106. Frantz C, Stewart KM, Weaver VM. 2010. The extracellular matrix at a glance. *J Cell Sci* 123:4195–4200. <https://doi.org/10.1242/jcs.023820>.
  107. Bonnans C, Chou J, Werb Z. 2014. Remodelling the extracellular matrix in development and disease. *Nat Rev Mol Cell Biol* 15:786–801. <https://doi.org/10.1038/nrm3904>.
  108. Ray SJ, Franki SN, Pierce RH, Dimitrova S, Kotliansky V, Sprague AG, Doherty PC, de Fougerolles AR, Topham DJ. 2004. The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. *Immunity* 20:167–179. [https://doi.org/10.1016/S1074-7613\(04\)00021-4](https://doi.org/10.1016/S1074-7613(04)00021-4).
  109. Mammoto T, Mammoto A, Ingber DE. 2013. Mechanobiology and developmental control. *Annu Rev Cell Dev Biol* 29:27–61. <https://doi.org/10.1146/annurev-cellbio-101512-122340>.
  110. Button B, Boucher RC, University of North Carolina Virtual Lung Group. 2008. Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. *Respir Physiol Neurobiol* 163:189–201. <https://doi.org/10.1016/j.resp.2008.04.020>.
  111. Gayer CP, Basson MD. 2009. The effects of mechanical forces on intestinal physiology and pathology. *Cell Signal* 21:1237–1244. <https://doi.org/10.1016/j.cellsig.2009.02.011>.
  112. Scott SM, Knowles CH, Wang D, Yazaki E, Picon L, Wingate DL, Lindberg G. 2006. The nocturnal jejunal migrating motor complex: defining normal ranges by study of 51 healthy adult volunteers and meta-analysis. *Neurogastroenterol Motil* 18:927–935. <https://doi.org/10.1111/j.1365-2982.2006.00824.x>.
  113. Otterson MF, Sarr MG. 1993. Normal physiology of small intestinal motility. *Surg Clin North Am* 73:1173–1192. [https://doi.org/10.1016/S0039-6109\(16\)46186-4](https://doi.org/10.1016/S0039-6109(16)46186-4).
  114. Guo P, Weinstein AM, Weinbaum S. 2000. A hydrodynamic mechanosensory hypothesis for brush border microvilli. *Am J Physiol Renal Physiol* 279:F698–F712. <https://doi.org/10.1152/ajprenal.2000.279.4.F698>.
  115. Ashida N, Takechi H, Kita T, Arai H. 2003. Vortex-mediated mechanical stress induces integrin-dependent cell adhesion mediated by inositol 1,4,5-trisphosphate-sensitive Ca<sup>2+</sup> release in THP-1 cells. *J Biol Chem* 278:9327–9331. <https://doi.org/10.1074/jbc.M212316200>.
  116. Kim M, Javed NH, Yu JG, Christofi F, Cooke HJ. 2001. Mechanical stimulation activates Galphaq signaling pathways and 5-hydroxytryptamine release from human carcinoid BON cells. *J Clin Invest* 108:1051–1059. <https://doi.org/10.1172/JCI12467>.
  117. Roskelley CD, Bissell MJ. 1995. Dynamic reciprocity revisited: a continuous, bidirectional flow of information between cells and the extracel-

- lular matrix regulates mammary epithelial cell function. *Biochem Cell Biol* 73:391–397. <https://doi.org/10.1139/o95-046>.
118. Zhang J, Owen CR, Sanders MA, Turner JR, Basson MD. 2006. The mitogenic effects of cyclic mechanical strain on intestinal epithelial monolayer wound closure are matrix dependent. *Gastroenterology* 131:1179–1189. <https://doi.org/10.1053/j.gastro.2006.08.007>.
  119. Zhang S, Kingsley RA, Santos RL, Andrews-Polymenis H, Raffatellu M, Figueiredo J, Nunes J, Tsolis RM, Adams LG, Baumler AJ. 2003. Molecular pathogenesis of *Salmonella enterica* serotype typhimurium-induced diarrhea. *Infect Immun* 71:1–12. <https://doi.org/10.1128/IAI.71.1.1-12.2003>.
  120. Lu P, Takai K, Weaver VM, Werb Z. 2011. Extracellular matrix degradation and remodeling in development and disease. *Cold Spring Harb Perspect Biol* 3:a005058. <https://doi.org/10.1101/cshperspect.a005058>.
  121. Abbott A. 2003. Cell culture: biology's new dimension. *Nature* 424:870–872. <https://doi.org/10.1038/424870a>.
  122. de Bentzmann S, Plotkowski C, Puchelle E. 1996. Receptors in the *Pseudomonas aeruginosa* adherence to injured and repairing airway epithelium. *Am J Respir Crit Care Med* 154:S155–S162. [https://doi.org/10.1164/ajrcm/154.4\\_Pt\\_2.S155](https://doi.org/10.1164/ajrcm/154.4_Pt_2.S155).
  123. de Bentzmann S, Roger P, Dupuit F, Bajolet-Laudinat O, Fuchey C, Plotkowski MC, Puchelle E. 1996. Asialo GM1 is a receptor for *Pseudomonas aeruginosa* adherence to regenerating respiratory epithelial cells. *Infect Immun* 64:1582–1588.
  124. Ljungh A, Moran AP, Wadstrom T. 1996. Interactions of bacterial adhesins with extracellular matrix and plasma proteins: pathogenic implications and therapeutic possibilities. *FEMS Immunol Med Microbiol* 16:117–126. <https://doi.org/10.1111/j.1574-695X.1996.tb00128.x>.
  125. Ljungh A, Wadstrom T. 1996. Interactions of bacterial adhesins with the extracellular matrix. *Adv Exp Med Biol* 408:129–140. [https://doi.org/10.1007/978-1-4613-0415-9\\_15](https://doi.org/10.1007/978-1-4613-0415-9_15).
  126. Plotkowski MC, Tournier JM, Puchelle E. 1996. *Pseudomonas aeruginosa* strains possess specific adhesins for laminin. *Infect Immun* 64:600–605.
  127. Wolf DA, Schwarz RP. 1991. Analysis of gravity-induced particle motion and fluid perfusion flow in the NASA-designed rotating zero-head space tissue culture vessel. NASA technical paper 3143. NASA Johnson Space Center, Houston, TX.
  128. Basson MD. 2003. Paradigms for mechanical signal transduction in the intestinal epithelium. *Digestion* 68:217–225. <https://doi.org/10.1159/000076385>.
  129. Beeson JG, Rogerson SJ, Cooke BM, Reeder JC, Chai W, Lawson AM, Molyneux ME, Brown GV. 2000. Adhesion of *Plasmodium falciparum*-infected erythrocytes to hyaluronic acid in placental malaria. *Nat Med* 6:86–90. <https://doi.org/10.1038/71582>.
  130. Cai Z, Xin J, Pollock DM, Pollock JS. 2000. Shear stress-mediated NO production in inner medullary collecting duct cells. *Am J Physiol Renal Physiol* 279:F270–F274. <https://doi.org/10.1152/ajprenal.2000.279.2.F270>.
  131. Creasy RK, Reznik R. 1984. Maternal-fetal medicine: principles and practice. WB Saunders Company, Philadelphia, PA.
  132. Stock UA, Vacanti JP. 2001. Cardiovascular physiology during fetal development and implications for tissue engineering. *Tissue Eng* 7:1–7. <https://doi.org/10.1089/107632701300003241>.
  133. Vetsch JR, Betts DC, Muller R, Hofmann S. 2017. Flow velocity-driven differentiation of human mesenchymal stromal cells in silk fibroin scaffolds: a combined experimental and computational approach. *PLoS One* 12:e0180781. <https://doi.org/10.1371/journal.pone.0180781>.
  134. Liu YS, Lee OK. 2014. In search of the pivot point of mechanotransduction: mechanosensing of stem cells. *Cell Transplant* 23:1–11. <https://doi.org/10.3727/096368912X659925>.
  135. Geuss LR, Suggs LJ. 2013. Making cardiomyocytes: how mechanical stimulation can influence differentiation of pluripotent stem cells. *Bio-technol Prog* 29:1089–1096. <https://doi.org/10.1002/btpr.1794>.
  136. Chen G, Lv Y, Guo P, Lin C, Zhang X, Yang L, Xu Z. 2013. Matrix mechanics and fluid shear stress control stem cells fate in three dimensional microenvironment. *Curr Stem Cell Res Ther* 8:313–323. <https://doi.org/10.2174/1574888X11308040007>.
  137. Adamo L, Garcia-Cardena G. 2011. Directed stem cell differentiation by fluid mechanical forces. *Antioxid Redox Signal* 15:1463–1473. <https://doi.org/10.1089/ars.2011.3907>.
  138. Ando J, Yamamoto K. 2009. Vascular mechanobiology: endothelial cell responses to fluid shear stress. *Circ J* 73:1983–1992. <https://doi.org/10.1253/circj.CJ-09-0583>.
  139. Patwari P, Lee RT. 2008. Mechanical control of tissue morphogenesis. *Circ Res* 103:234–243. <https://doi.org/10.1161/CIRCRESAHA.108.175331>.
  140. Miura S, Sato K, Kato-Negishi M, Teshima T, Takeuchi S. 2015. Fluid shear triggers microvilli formation via mechanosensitive activation of TRPV6. *Nat Commun* 6:8871. <https://doi.org/10.1038/ncomms9871>.
  141. Jessup JM, Frantz M, Sonmez-Alpan E, Locker J, Skena K, Waller H, Battle P, Nachman A, Weber ME, Thomas DA, Curbeam RL, Jr, Baker TL, Goodwin TJ. 2000. Microgravity culture reduces apoptosis and increases the differentiation of a human colorectal carcinoma cell line. *In Vitro Cell Dev Biol Anim* 36:367–373.
  142. Zhou HE, Goodwin TJ, Chang SM, Baker TL, Chung LW. 1997. Establishment of a three-dimensional human prostate organoid coculture under microgravity-simulated conditions: evaluation of androgen-induced growth and PSA expression. *In Vitro Cell Dev Biol Anim* 33:375–380.
  143. Alcantara Warren C, Destura RV, Sevilleja JE, Barroso LF, Carvalho H, Barrett LJ, O'Brien AD, Guerrant RL. 2008. Detection of epithelial-cell injury, and quantification of infection, in the HCT-8 organoid model of cryptosporidiosis. *J Infect Dis* 198:143–149. <https://doi.org/10.1086/588819>.
  144. Carterson AJ, Honer zu Bentrup K, Ott CM, Clarke MS, Pierson DL, Vanderburg CR, Buchanan KL, Nickerson CA, Schurr MJ. 2005. A549 lung epithelial cells grown as three-dimensional aggregates: alternative tissue culture model for *Pseudomonas aeruginosa* pathogenesis. *Infect Immun* 73:1129–1140. <https://doi.org/10.1128/IAI.73.2.1129-1140.2005>.
  145. Carvalho HM, Teel LD, Goping G, O'Brien AD. 2005. A three-dimensional tissue culture model for the study of attach and efface lesion formation by enteropathogenic and enterohaemorrhagic *Escherichia coli*. *Cell Microbiol* 7:1771–1781. <https://doi.org/10.1111/j.1462-5822.2004.00594.x>.
  146. Drummond CG, Nickerson CA, Coyne CB. 2016. A three-dimensional cell culture model to study enterovirus infection of polarized intestinal epithelial cells. *mSphere* 1:e00030-15. <https://doi.org/10.1128/mSphere.00030-15>.
  147. David J, Sayer NM, Sarkar-Tyson M. 2014. The use of a three-dimensional cell culture model to investigate host-pathogen interactions of *Francisella tularensis* in human lung epithelial cells. *Microbes Infect* 16:735–745. <https://doi.org/10.1016/j.micinf.2014.04.001>.
  148. Chang TT, Hughes-Fulford M. 2014. Molecular mechanisms underlying the enhanced functions of three-dimensional hepatocyte aggregates. *Biomaterials* 35:2162–2171. <https://doi.org/10.1016/j.biomaterials.2013.11.063>.
  149. Hjeltn BE, Berta AN, Nickerson CA, Arntzen CJ, Herbst-Kralovetz MM. 2010. Development and characterization of a three-dimensional organotypic human vaginal epithelial cell model. *Biol Reprod* 82:617–627. <https://doi.org/10.1095/biolreprod.109.080408>.
  150. LaMarca HL, Ott CM, Honer Zu Bentrup K, LeBlanc CL, Pierson DL, Nelson AB, Scandurro AB, Whitley GS, Nickerson CA, Morris CA. 2005. Three-dimensional growth of extravillous cytotrophoblasts promotes differentiation and invasion. *Placenta* 26:709–720. <https://doi.org/10.1016/j.placenta.2004.11.003>.
  151. McConkey CA, Delorme-Axford E, Nickerson CA, Kim KS, Sadovsky Y, Boyle JP, Coyne CB. 2016. A three-dimensional culture system recapitulates placental syncytiotrophoblast development and microbial resistance. *Sci Adv* 2:e1501462. <https://doi.org/10.1126/sciadv.1501462>.
  152. Radtke AL, Wilson JW, Sarker S, Nickerson CA. 2010. Analysis of interactions of *Salmonella* type three secretion mutants with 3-D intestinal epithelial cells. *PLoS One* 5:e15750. <https://doi.org/10.1371/journal.pone.0015750>.
  153. Sainz B, Jr, TenCate V, Uprichard SL. 2009. Three-dimensional Huh7 cell culture system for the study of hepatitis C virus infection. *Virology* 396:103–113. <https://doi.org/10.1186/1743-422X-6-103>.
  154. Duray PH, Hatfill SJ, Pellis NR. 1997. Tissue culture in microgravity. *Sci Med* 4:46–55.
  155. Michalopoulos G, Pitot HC. 1975. Primary culture of parenchymal liver cells on collagen membranes. Morphological and biochemical observations. *Exp Cell Res* 94:70–78.
  156. Emerman JT, Pitelka DR. 1977. Maintenance and induction of morphological differentiation in dissociated mammary epithelium on floating collagen membranes. *In Vitro* 13:316–328.
  157. Nickerson CA, Ott CM, Wilson JW, Ramamurthy R, LeBlanc CL, Honer zu Bentrup K, Hammond T, Pierson DL. 2003. Low-shear modeled microgravity: a global environmental regulatory signal affecting bac-

- terial gene expression, physiology, and pathogenesis. *J Microbiol Methods* 54:1–11. [https://doi.org/10.1016/S0167-7012\(03\)00018-6](https://doi.org/10.1016/S0167-7012(03)00018-6).
158. Soni A, O'Sullivan L, Quick LN, Ott CM, Nickerson CA, Wilson JW. 2014. Conservation of the low-shear modeled microgravity response in Enterobacteriaceae and analysis of the *trp* genes in this response. *Open Microbiol J* 8:51–58. <https://doi.org/10.2174/1874285801408010051>.
  159. Grant KC, Khodadad CLM, Foster JS. 2013. Role of Hfq in an animal-microbe symbiosis under simulated microgravity conditions. *Int J Astrobiol* 13:53–61. <https://doi.org/10.1017/S1473550413000359>.
  160. Altenburg SD, Nielsen-Preiss SM, Hyman LE. 2008. Increased filamentous growth of *Candida albicans* in simulated microgravity. *Genomics Proteomics Bioinformatics* 6:42–50. [https://doi.org/10.1016/S1672-0229\(08\)60019-4](https://doi.org/10.1016/S1672-0229(08)60019-4).
  161. Baker PW, Meyer ML, Leff LG. 2004. *Escherichia coli* growth under modeled reduced gravity. *Microgravity Sci Technol* 15:39–44. <https://doi.org/10.1007/BF02870967>.
  162. Demain AL, Fang A. 2001. Secondary metabolism in simulated microgravity. *Chem Rec* 1:333–346. <https://doi.org/10.1002/tcr.1018>.
  163. Fang A, Pierson DL, Koenig DW, Mishra SK, Demain AL. 1997. Effect of simulated microgravity and shear stress on microcin B17 production by *Escherichia coli* and on its excretion into the medium. *Appl Environ Microbiol* 63:4090–4092.
  164. Lynch SV, Brodie EL, Matin A. 2004. Role and regulation of sigma S in general resistance conferred by low-shear simulated microgravity in *Escherichia coli*. *J Bacteriol* 186:8207–8212. <https://doi.org/10.1128/JB.186.24.8207-8212.2004>.
  165. Tucker DL, Ott CM, Huff S, Fofanov Y, Pierson DL, Willson RC, Fox GE. 2007. Characterization of *Escherichia coli* MG1655 grown in a low-shear modeled microgravity environment. *BMC Microbiol* 7:15. <https://doi.org/10.1186/1471-2180-7-15>.
  166. Abshire CF, Prasai K, Soto I, Shi R, Concha M, Baddoo M, Flemington EK, Ennis DG, Scott RS, Harrison L. 2016. Exposure of *Mycobacterium marinum* to low-shear modeled microgravity: effect on growth, the transcriptome and survival under stress. *NPJ Microgravity* 2:16038. <https://doi.org/10.1038/npmjgrav.2016.38>.
  167. Orsini SS, Lewis AM, Rice KC. 2017. Investigation of simulated microgravity effects on *Streptococcus mutans* physiology and global gene expression. *NPJ Microgravity* 3:4. <https://doi.org/10.1038/s41526-016-0006-4>.
  168. Goodwin TJ, Schroeder WF, Wolf DA, Moyer MP. 1993. Rotating-wall vessel coculture of small intestine as a prelude to tissue modeling: aspects of simulated microgravity. *Proc Soc Exp Biol Med* 202:181–192.
  169. Straub TM, Honer zu Bentrop K, Orosz-Coghlan P, Dohnalkova A, Mayer BK, Bartholomew RA, Valdez CO, Bruckner-Lea CJ, Gerba CP, Abbaszadegan M, Nickerson CA. 2007. In vitro cell culture infectivity assay for human noroviruses. *Emerg Infect Dis* 13:396–403. <https://doi.org/10.3201/eid1303.060549>.
  170. Skardal A, Sarker SF, Crabbé A, Nickerson CA, Prestwich GD. 2010. The generation of 3-D tissue models based on hyaluronan hydrogel-coated microcarriers within a rotating wall vessel bioreactor. *Biomaterials* 31:8426–8435. <https://doi.org/10.1016/j.biomaterials.2010.07.047>.
  171. Barrila J, Yang J, Crabbé A, Sarker SF, Liu Y, Ott CM, Nelman-Gonzalez MA, Clemett SJ, Nydam SD, Forsyth RJ, Davis RR, Crucian BE, Quiariarte H, Roland KL, Brenneman K, Sams C, Loscher C, Nickerson CA. 2017. Three-dimensional organotypic co-culture model of intestinal epithelial cells and macrophages to study *Salmonella enterica* colonization patterns. *NPJ Microgravity* 3:10. <https://doi.org/10.1038/s41526-017-0011-2>.
  172. De Weirdt R, Crabbé A, Roos S, Vollenweider S, Lacroix C, van Pijkeren JP, Britton RA, Sarker S, Van de Wiele T, Nickerson CA. 2012. Glycerol supplementation enhances *L. reuteri*'s protective effect against *S. Typhimurium* colonization in a 3-D model of colonic epithelium. *PLoS One* 7:e37116. <https://doi.org/10.1371/journal.pone.0037116>.
  173. Goodwin TJ, Jessup JM, Wolf DA. 1992. Morphologic differentiation of colon carcinoma cell lines HT-29 and HT-29KM in rotating-wall vessels. *In Vitro Cell Dev Biol* 28A:47–60.
  174. Devarasetty M, Wang E, Soker S, Skardal A. 2017. Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy. *Biofabrication* 9:021002. <https://doi.org/10.1088/1758-5090/aa7484>.
  175. Salerno-Goncalves R, Fasano A, Szein MB. 2011. Engineering of a multicellular organotypic model of the human intestinal mucosa. *Gastroenterology* 141:e18–e20. <https://doi.org/10.1053/j.gastro.2011.04.062>.
  176. Salerno-Goncalves R, Fasano A, Szein MB. 2016. Development of a multicellular three-dimensional organotypic model of the human intestinal mucosa grown under microgravity. *J Vis Exp* 2016(113):e54148. <https://doi.org/10.3791/54148>.
  177. Salerno-Goncalves R, Safavie F, Fasano A, Szein MB. 2016. Free and complexed-secretory immunoglobulin A triggers distinct intestinal epithelial cell responses. *Clin Exp Immunol* 185:338–347. <https://doi.org/10.1111/cei.12801>.
  178. Crabbé A, Liu Y, Matthijs N, Rigole P, De La Fuente-Nunez C, Davis R, Ledesma MA, Sarker S, Van Houdt R, Hancock RE, Coenye T, Nickerson CA. 2017. Antimicrobial efficacy against *Pseudomonas aeruginosa* biofilm formation in a three-dimensional lung epithelial model and the influence of fetal bovine serum. *Sci Rep* 7:43321. <https://doi.org/10.1038/srep43321>.
  179. Crabbé A, Liu Y, Sarker SF, Bonenfant NR, Barrila J, Borg ZD, Lee JJ, Weiss DJ, Nickerson CA. 2015. Recellularization of decellularized lung scaffolds is enhanced by dynamic suspension culture. *PLoS One* 10:e0126846. <https://doi.org/10.1371/journal.pone.0126846>.
  180. Crabbé A, Sarker SF, Van Houdt R, Ott CM, Leys N, Cornelis P, Nickerson CA. 2011. Alveolar epithelium protects macrophages from quorum sensing-induced cytotoxicity in a three-dimensional co-culture model. *Cell Microbiol* 13:469–481. <https://doi.org/10.1111/j.1462-5822.2010.01548.x>.
  181. Cortiella J, Niles J, Cantu A, Brettler A, Pham A, Vargas G, Winston S, Wang J, Walls S, Nichols JE. 2010. Influence of acellular natural lung matrix on murine embryonic stem cell differentiation and tissue formation. *Tissue Eng Part A* 16:2565–2580. <https://doi.org/10.1089/ten.tea.2009.0730>.
  182. Goodwin TJ, McCarthy M, Cohrs RJ, Kaufer BB. 2015. 3D tissue-like assemblies: a novel approach to investigate virus-cell interactions. *Methods* 90:76–84. <https://doi.org/10.1016/j.jymeth.2015.05.010>.
  183. Skardal A, Devarasetty M, Rodman C, Atala A, Soker S. 2015. Liver-tumor hybrid organoids for modeling tumor growth and drug response in vitro. *Ann Biomed Eng* 43:2361–2373. <https://doi.org/10.1007/s10439-015-1298-3>.
  184. Khaoustov VI, Darlington GJ, Soriano HE, Krishnan B, Risin D, Pellis NR, Yoffe B. 1999. Induction of three-dimensional assembly of human liver cells by simulated microgravity. *In Vitro Cell Dev Biol Anim* 35:501–509.
  185. Prewett TL, Goodwin TJ, Spaulding GF. 1993. Three-dimensional modeling of T-24 human bladder carcinoma cell line: a new simulated microgravity culture vessel. *J Tissue Cult Methods* 15:29–36.
  186. Ingram M, Tschy GB, Saroufeem R, Yazan O, Narayan KS, Goodwin TJ, Spaulding GF. 1997. Three-dimensional growth patterns of various human tumor cell lines in simulated microgravity of a NASA bioreactor. *In Vitro Cell Dev Biol Anim* 33:459–466.
  187. Smith YC, Grande KK, Rasmussen SB, O'Brien AD. 2006. Novel three-dimensional organoid model for evaluation of the interaction of uropathogenic *Escherichia coli* with terminally differentiated human urothelial cells. *Infect Immun* 74:750–757. <https://doi.org/10.1128/IAI.74.1.750-757.2006>.
  188. Łaniewski P, Gomez A, Hire G, So M, Herbst-Kralovetz MM. 2017. Human three-dimensional endometrial epithelial cell model to study host interactions with vaginal bacteria and *Neisseria gonorrhoeae*. *Infect Immun* 85:e01049-16. <https://doi.org/10.1128/IAI.01049-16>.
  189. McGowan CL, Radtke AL, Abraham K, Martin DH, Herbst-Kralovetz M. 2013. *Mycoplasma genitalium* infection activates cellular host defense and inflammation pathways in a 3-dimensional human endocervical epithelial cell model. *J Infect Dis* 207:1857–1868. <https://doi.org/10.1093/infdis/jit101>.
  190. Doerflinger SY, Throop AL, Herbst-Kralovetz MM. 2014. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. *J Infect Dis* 209:1989–1999. <https://doi.org/10.1093/infdis/jiu004>.
  191. Bursac N, Loo Y, Leong K, Tung L. 2007. Novel anisotropic engineered cardiac tissues: studies of electrical propagation. *Biochem Biophys Res Commun* 361:847–853. <https://doi.org/10.1016/j.bbrc.2007.07.138>.
  192. Rungarunlert S, Klincumhom N, Bock I, Nemes C, Techakumphu M, Pirity MK, Dinnyes A. 2011. Enhanced cardiac differentiation of mouse embryonic stem cells by use of the slow-turning, lateral vessel (STLV) bioreactor. *Biotechnol Lett* 33:1565–1573. <https://doi.org/10.1007/s10529-011-0614-8>.
  193. Papadaki M, Bursac N, Langer R, Merok J, Vunjak-Novakovic G, Freed LE. 2001. Tissue engineering of functional cardiac muscle: molecular, struc-

- tural, and electrophysiological studies. *Am J Physiol Heart Circ Physiol* 280:H168–H178. <https://doi.org/10.1152/ajpheart.2001.280.1.H168>.
194. Margolis L, Hatfil S, Chuauqui R, Vocke C, Emmert-Buck M, Linehan WM, Duray PH. 1999. Long term organ culture of human prostate tissue in a NASA-designed rotating wall bioreactor. *J Urol* 161:290–297.
  195. Rose MI, Brown DC, Pellis NR, Crisera CA, Colen KL, Longaker MT, Gittes GK. 1999. Effects of microgravity on the embryonic pancreas. *In Vitro Cell Dev Biol Anim* 35:560–563.
  196. Murray HE, Paget MB, Downing R. 2005. Preservation of glucose responsiveness in human islets maintained in a rotational cell culture system. *Mol Cell Endocrinol* 238:39–49. <https://doi.org/10.1016/j.mce.2005.03.014>.
  197. Lelkes PI, Galvan DL, Hayman GT, Goodwin TJ, Chatman DY, Cherian S, Garcia RM, Unsworth BR. 1998. Simulated microgravity conditions enhance differentiation of cultured PC12 cells towards the neuroendocrine phenotype. *In Vitro Cell Dev Biol Anim* 34:316–325.
  198. Myers TA, Nickerson CA, Kaushal D, Ott CM, Höner zu Benstrup K, Ramamurthy R, Nelman-Gonzalez M, Pierson DL, Philipp MT. 2008. Closing the phenotypic gap between transformed neuronal cell lines in culture and untransformed neurons. *J Neurosci Methods* 174:31–41. <https://doi.org/10.1016/j.jneumeth.2008.06.031>.
  199. Valmikinathan CM, Hoffman J, Yu X. 2011. Impact of scaffold micro and macro architecture on Schwann cell proliferation under dynamic conditions in a rotating wall vessel bioreactor. *Mater Sci Eng C Mater Biol Appl* 31:22–29. <https://doi.org/10.1016/j.msec.2010.04.001>.
  200. Bramley JC, Drummond CG, Lennemann NJ, Good CA, Kim KS, Coyne CB. 2017. A three-dimensional cell culture system to model RNA virus infections at the blood-brain barrier. *mSphere* 2:e00206-17. <https://doi.org/10.1128/mSphere.00206-17>.
  201. Lei XH, Ning LN, Cao YJ, Liu S, Zhang SB, Qiu ZF, Hu HM, Zhang HS, Liu S, Duan EK. 2011. NASA-approved rotary bioreactor enhances proliferation of human epidermal stem cells and supports formation of 3D epidermis-like structure. *PLoS One* 6:e26603. <https://doi.org/10.1371/journal.pone.0026603>.
  202. DiStefano T, Chen HY, Panebianco C, Kaya KD, Brooks MJ, Gieser L, Morgan NY, Pohida T, Swaroop A. 2018. Accelerated and improved differentiation of retinal organoids from pluripotent stem cells in rotating-wall vessel bioreactors. *Stem Cell Rep* 10:300–313. <https://doi.org/10.1016/j.stemcr.2017.11.001>.
  203. Botchwey EA, Pollack SR, Levine EM, Laurencin CT. 2001. Bone tissue engineering in a rotating bioreactor using a microcarrier matrix system. *J Biomed Mater Res* 55:242–253. [https://doi.org/10.1002/1097-4636\(200105\)55:2<242::AID-JBM1011>3.0.CO;2-D](https://doi.org/10.1002/1097-4636(200105)55:2<242::AID-JBM1011>3.0.CO;2-D).
  204. Detamore MS, Athanasiou KA. 2005. Use of a rotating bioreactor toward tissue engineering the temporomandibular joint disc. *Tissue Eng* 11:1188–1197. <https://doi.org/10.1089/ten.2005.11.1188>.
  205. Yang X, Wang D, Hao J, Gong M, Arlet V, Balian G, Shen FH, Li XJ. 2011. Enhancement of matrix production and cell proliferation in human annulus cells under bioreactor culture. *Tissue Eng Part A* 17:1595–1603. <https://doi.org/10.1089/ten.tea.2010.0449>.
  206. Rauh J, Milan F, Gunther KP, Stiehler M. 2011. Bioreactor systems for bone tissue engineering. *Tissue Eng Part B Rev* 17:263–280. <https://doi.org/10.1089/ten.teb.2010.0612>.
  207. Ulbrich C, Wehland M, Pietsch J, Aleshcheva G, Wise P, van Loon J, Magnusson N, Infanger M, Grosse J, Eilles C, Sundaresan A, Grimm D. 2014. The impact of simulated and real microgravity on bone cells and mesenchymal stem cells. *Biomed Res Int* 2014:928507. <https://doi.org/10.1155/2014/928507>.
  208. Duray PH, Yin SR, Ito Y, Bezrukov L, Cox C, Cho MS, Fitzgerald W, Dorward D, Zimmerberg J, Margolis L. 2005. Invasion of human tissue ex vivo by *Borrelia burgdorferi*. *J Infect Dis* 191:1747–1754. <https://doi.org/10.1086/429632>.
  209. Duke J, Daane E, Arizpe J, Montufar-Solis D. 1996. Chondrogenesis in aggregates of embryonic limb cells grown in a rotating wall vessel. *Adv Space Res* 17:289–293.
  210. Darwin KH, Miller VL. 1999. Molecular basis of the interaction of *Salmonella* with the intestinal mucosa. *Clin Microbiol Rev* 12:405–428.
  211. Coombes BK, Coburn BA, Potter AA, Gomis S, Mirakhor K, Li Y, Finlay BB. 2005. Analysis of the contribution of *Salmonella* pathogenicity islands 1 and 2 to enteric disease progression using a novel bovine ileal loop model and a murine model of infectious enterocolitis. *Infect Immun* 73:7161–7169. <https://doi.org/10.1128/IAI.73.11.7161-7169.2005>.
  212. Hapfelmeier S, Stecher B, Barthel M, Kremer M, Müller AJ, Heikenwalder M, Stallmach T, Hensel M, Pfeffer K, Akira S, Hardt WD. 2005. The *Salmonella* pathogenicity island (SPI)-2 and SPI-1 type III secretion systems allow *Salmonella* serovar typhimurium to trigger colitis via MyD88-dependent and MyD88-independent mechanisms. *J Immunol* 174:1675–1685. <https://doi.org/10.4049/jimmunol.174.3.1675>.
  213. Hu Q, Coburn B, Deng W, Li Y, Shi X, Lan Q, Wang B, Coombes BK, Finlay BB. 2008. *Salmonella enterica* serovar Senftenberg human clinical isolates lacking SPI-1. *J Clin Microbiol* 46:1330–1336. <https://doi.org/10.1128/JCM.01255-07>.
  214. Kamada N, Chen GY, Inohara N, Nunez G. 2013. Control of pathogens and pathobionts by the gut microbiota. *Nat Immunol* 14:685–690. <https://doi.org/10.1038/ni.2608>.
  215. Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, Harris D, Clarke L, Whitehead S, Sangal V, Marsh K, Achtman M, Molyneux ME, Cormican M, Parkhill J, MacLennan CA, Heyderman RS, Dougan G. 2009. Epidemic multiple drug resistant *Salmonella* Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. *Genome Res* 19:2279–2287. <https://doi.org/10.1101/gr.091017.109>.
  216. Shieh JTC, Bergelson JM. 2002. Interaction with decay-accelerating factor facilitates coxsackievirus B infection of polarized epithelial cells. *J Virol* 76:9474–9480. <https://doi.org/10.1128/JVI.76.18.9474-9480.2002>.
  217. Patel KP, Coyne CB, Bergelson JM. 2009. Dynamamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells. *J Virol* 83:11064–11077. <https://doi.org/10.1128/JVI.01016-09>.
  218. Coyne CB, Bergelson JM. 2006. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. *Cell* 124:119–131. <https://doi.org/10.1016/j.cell.2005.10.035>.
  219. Pan J, Zhang L, Odenwald MA, Shen L, Turner JR, Bergelson JM. 2015. Expression of human decay-accelerating factor on intestinal epithelium of transgenic mice does not facilitate infection by the enteral route. *J Virol* 89:4311–4318. <https://doi.org/10.1128/JVI.03468-14>.
  220. Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ. 2015. TEER measurement techniques for in vitro barrier model systems. *J Lab Autom* 20:107–126. <https://doi.org/10.1177/2211068214561025>.
  221. Nickerson CA, Ott CM. 2004. A new dimension in modeling infectious disease. *ASM News* 70:169–175.
  222. Fatehullah A, Tan SH, Barker N. 2016. Organoids as an in vitro model of human development and disease. *Nat Cell Biol* 18:246–254. <https://doi.org/10.1038/ncb3312>.
  223. Flora AD, Teel LD, Smith MA, Sinclair JF, Melton-Celsa AR, O'Brien AD. 2013. Ricin crosses polarized human intestinal cells and intestines of ricin-gavaged mice without evident damage and then disseminates to mouse kidneys. *PLoS One* 8:e69706. <https://doi.org/10.1371/journal.pone.0069706>.
  224. Bergmann S, Steinert M. 2015. From single cells to engineered and explanted tissues: new perspectives in bacterial infection biology. *Int Rev Cell Mol Biol* 319:1–44. <https://doi.org/10.1016/bs.ircmb.2015.06.003>.
  225. Astashkina A, Grainger DW. 2014. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. *Adv Drug Deliv Rev* 69–70:1–18.
  226. Shamir ER, Ewald AJ. 2014. Three-dimensional organotypic culture: experimental models of mammalian biology and disease. *Nat Rev Mol Cell Biol* 15:647–664. <https://doi.org/10.1038/nrm3873>.
  227. Bhat R, Bissell MJ. 2014. Of plasticity and specificity: dialectics of the microenvironment and macroenvironment and the organ phenotype. *Wiley Interdiscip Rev Dev Biol* 3:147–163. <https://doi.org/10.1002/wdev.130>.
  228. Bissell MJ. 2017. Goodbye flat biology—time for the 3rd and the 4th dimensions. *J Cell Sci* 130:3–5. <https://doi.org/10.1242/jcs.200550>.
  229. Cruz-Acuña R, Quiros M, Farkas AE, Dedhia PH, Huang S, Siuda D, Garcia-Hernandez V, Miller AJ, Spence JR, Nusrat A, Garcia AJ. 2017. Synthetic hydrogels for human intestinal organoid generation and colonic wound repair. *Nat Cell Biol* 19:1326–1335. <https://doi.org/10.1038/ncb3632>.
  230. Bartfeld S. 2016. Modeling infectious diseases and host-microbe interactions in gastrointestinal organoids. *Dev Biol* 420:262–270. <https://doi.org/10.1016/j.ydbio.2016.09.014>.
  231. Bartfeld S, Clevers H. 2017. Stem cell-derived organoids and their application for medical research and patient treatment. *J Mol Med* 95:729–738. <https://doi.org/10.1007/s00109-017-1531-7>.
  232. Finkbeiner SR, Spence JR. 2013. A gutsy task: generating intestinal

- tissue from human pluripotent stem cells. *Dig Dis Sci* 58:1176–1184. <https://doi.org/10.1007/s10620-013-2620-2>.
233. Hill DR, Spence JR. 2017. Gastrointestinal organoids: understanding the molecular basis of the host-microbe interface. *Cell Mol Gastroenterol Hepatol* 3:138–149. <https://doi.org/10.1016/j.jcmgh.2016.11.007>.
  234. In JG, Foulke-Abel J, Estes MK, Zachos NC, Kovbasnjuk O, Donowitz M. 2016. Human mini-guts: new insights into intestinal physiology and host-pathogen interactions. *Nat Rev Gastroenterol Hepatol* 13:633–642. <https://doi.org/10.1038/nrgastro.2016.142>.
  235. Zachos NC, Kovbasnjuk O, Foulke-Abel J, In J, Blutt SE, de Jonge HR, Estes MK, Donowitz M. 2016. Human enteroids/colonoids and intestinal organoids functionally recapitulate normal intestinal physiology and pathophysiology. *J Biol Chem* 291:3759–3766. <https://doi.org/10.1074/jbc.R114.635995>.
  236. Merker SR, Weitz J, Stange DE. 2016. Gastrointestinal organoids: how they gut it out. *Dev Biol* 420:239–250. <https://doi.org/10.1016/j.ydbio.2016.08.010>.
  237. Dutta D, Clevers H. 2017. Organoid culture systems to study host-pathogen interactions. *Curr Opin Immunol* 48:15–22. <https://doi.org/10.1016/j.coi.2017.07.012>.
  238. Dedhia PH, Bertaux-Skeirik N, Zavros Y, Spence JR. 2016. Organoid models of human gastrointestinal development and disease. *Gastroenterology* 150:1098–1112. <https://doi.org/10.1053/j.gastro.2015.12.042>.
  239. Anonymous. 2018. Method of the year 2017: organoids. *Nat Methods* 15:1.
  240. Zhang YG, Wu S, Xia Y, Sun J. 2014. Salmonella-infected crypt-derived intestinal organoid culture system for host-bacterial interactions. *Physiol Rep* 2:e12147. <https://doi.org/10.14814/phy.2.12147>.
  241. Bhushal S, Wolfsmuller M, Selvakumar TA, Kemper L, Wirth D, Horne MW, Hauser H, Koster M. 2017. Cell polarization and epigenetic status shape the heterogeneous response to type iii interferons in intestinal epithelial cells. *Front Immunol* 8:671. <https://doi.org/10.3389/fimmu.2017.00671>.
  242. Davies JM, Santaolalla R, von Furstenberg RJ, Henning SJ, Abreu MT. 2015. The viral mimetic polyinosinic:polycytidylic acid alters the growth characteristics of small intestinal and colonic crypt cultures. *PLoS One* 10:e0138531. <https://doi.org/10.1371/journal.pone.0138531>.
  243. Wilson SS, Tocchi A, Holly MK, Parks WC, Smith JG. 2014. A small intestinal organoid model of non-invasive enteric pathogen-epithelial cell interactions. *Mucosal Immunol* 8:352–361. <https://doi.org/10.1038/mi.2014.72>.
  244. Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, Tuysuz N, Dekkers JF, Wang Y, de Jonge J, Sprengers D, van der Laan LJW, Beekman JM, ten Berge D, Metselaar HJ, de Jonge H, Koopmans MPG, Peppelenbosch MP, Pan Q. 2015. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. *Antiviral Res* 123:120–131. <https://doi.org/10.1016/j.antiviral.2015.09.010>.
  245. Aladegbami B, Barron L, Bao J, Colasanti J, Erwin CR, Warner BW, Guo J. 2017. Epithelial cell specific Raptor is required for initiation of type 2 mucosal immunity in small intestine. *Sci Rep* 7:5580. <https://doi.org/10.1038/s41598-017-06070-w>.
  246. Cao L, Kuratnik A, Xu W, Gibson JD, Kolling F, IV, Falcone ER, Ammar M, Van Heyst MD, Wright DL, Nelson CE, Giardina C. 2015. Development of intestinal organoids as tissue surrogates: cell composition and the epigenetic control of differentiation. *Mol Carcinog* 54:189–202. <https://doi.org/10.1002/mc.22089>.
  247. Fischer JC, Bscheider M, Eisenkolb G, Lin CC, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, Porosnicu Rodriguez KA, Calafiore M, Liebermann S, Liu C, Lienenklaus S, Weiss S, Kalinke U, Ruland J, Peschel C, Shono Y, Docampo M, Velardi E, Jenq RR, Hanash AM, Dudakov JA, Haas T, van den Brink MRM, Poeck H. 2017. RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. *Sci Transl Med* 9:eaag2513. <https://doi.org/10.1126/scitranslmed.aag2513>.
  248. Foulke-Abel J, In J, Yin J, Zachos NC, Kovbasnjuk O, Estes MK, de Jonge H, Donowitz M. 2016. Human enteroids as a model of upper small intestinal ion transport physiology and pathophysiology. *Gastroenterology* 150:638–649.e8. <https://doi.org/10.1053/j.gastro.2015.11.047>.
  249. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H. 2009. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature* 459:262–265. <https://doi.org/10.1038/nature07935>.
  250. Dekkers JF, Wiegierinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NWM, Bijvelds MJC, Scholte BJ, Nieuwenhuis EES, van den Brink S, Clevers H, van der Ent CK, Middendorp S, Beekman JM. 2013. A functional CFTR assay using primary cystic fibrosis intestinal organoids. *Nat Med* 19:939. <https://doi.org/10.1038/nm.3201>.
  251. de Lau W, Kujala P, Schneeberger K, Middendorp S, Li VS, Barker N, Martens A, Hofhuis F, DeKoter RP, Peters PJ, Nieuwenhuis E, Clevers H. 2012. Peyer's patch M cells derived from Lgr5<sup>+</sup> stem cells require SpiB and are induced by RankL in cultured "miniguts." *Mol Cell Biol* 32:3639–3647. <https://doi.org/10.1128/MCB.00434-12>.
  252. McCracken KW, Howell JC, Wells JM, Spence JR. 2011. Generating human intestinal tissue from pluripotent stem cells in vitro. *Nat Protoc* 6:1920–1928. <https://doi.org/10.1038/nprot.2011.410>.
  253. Ootani A, Li X, Sangiorgi E, Ho QT, Ueno H, Toda S, Sugihara H, Fujimoto K, Weissman IL, Capecchi MR, Kuo CJ. 2009. Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. *Nat Med* 15:701. <https://doi.org/10.1038/nm.1951>.
  254. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. 2012. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. *Nature* 470:105–109. <https://doi.org/10.1038/nature09691>.
  255. Rodríguez-Colman MJ, Schewe M, Meerlo M, Stigter E, Gerrits J, Pras-Raves M, Sacchetti A, Hornsveld M, Oost KC, Snippert HJ, Verhoeven-Duif N, Fodde R, Burgering BMT. 2017. Interplay between metabolic identities in the intestinal crypt supports stem cell function. *Nature* 543:424. <https://doi.org/10.1038/nature21673>.
  256. Workman MJ, Mahe MM, Trisno S, Poling HM, Watson CL, Sundaram N, Chang C-F, Schiesser J, Aubert P, Stanley EG, Elefanty AG, Miyaoka Y, Mandegar MA, Conklin BR, Neunlist M, Brugmann SA, Helmuth MA, Wells JM. 2017. Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. *Nat Med* 23:49–59. <https://doi.org/10.1038/nm.4233>.
  257. Forbester JL, Goulding D, Vallier L, Hannan N, Hale C, Pickard D, Mukhopadhyay S, Dougan G. 2015. Interaction of Salmonella enterica serovar Typhimurium with intestinal organoids derived from human induced pluripotent stem cells. *Infect Immun* 83:2926–2934. <https://doi.org/10.1128/IAI.00161-15>.
  258. Engevik MA, Engevik KA, Yacyshyn MB, Wang J, Hassett DJ, Darien B, Yacyshyn BR, Worrell RT. 2015. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile. *Am J Physiol Gastrointest Liver Physiol* 308:G497–G509. <https://doi.org/10.1152/ajpgi.00090.2014>.
  259. Engevik MA, Yacyshyn MB, Engevik KA, Wang J, Darien B, Hassett DJ, Yacyshyn BR, Worrell RT. 2015. Human Clostridium difficile infection: altered mucus production and composition. *Am J Physiol Gastrointest Liver Physiol* 308:G510–G524. <https://doi.org/10.1152/ajpgi.00091.2014>.
  260. Karve SS, Pradhan S, Ward DV, Weiss AA. 2017. Intestinal organoids model human responses to infection by commensal and Shiga toxin producing Escherichia coli. *PLoS One* 12:e0178966. <https://doi.org/10.1371/journal.pone.0178966>.
  261. In J, Foulke-Abel J, Zachos NC, Hansen A-M, Kaper JB, Bernstein HD, Halushka M, Blutt S, Estes MK, Donowitz M, Kovbasnjuk O. 2016. Enterohemorrhagic Escherichia coli reduces mucus and intermicrovillar bridges in human stem cell-derived colonoids. *Cell Mol Gastroenterol Hepatol* 2:48–62.e3. <https://doi.org/10.1016/j.jcmgh.2015.10.001>.
  262. Leslie JL, Huang S, Opp JS, Nagy MS, Kobayashi M, Young VB, Spence JR. 2015. Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function. *Infect Immun* 83:138–145. <https://doi.org/10.1128/IAI.02561-14>.
  263. Tao L, Zhang J, Meraner P, Tovaglieri A, Wu X, Gerhard R, Zhang X, Stallcup WB, Miao J, He X, Hurdle JG, Breault DT, Brass AL, Dong M. 2016. Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. *Nature* 538:350–355. <https://doi.org/10.1038/nature19799>.
  264. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD, Clevers H. 2011. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* 141:1762–1772. <https://doi.org/10.1053/j.gastro.2011.07.050>.
  265. Cristobal A, van den Toorn HWP, van de Wetering M, Clevers H, Heck AJR, Mohammed S. 2017. Personalized proteome profiles of healthy and tumor human colon organoids reveal both individual diversity and

- basic features of colorectal cancer. *Cell Rep* 18:263–274. <https://doi.org/10.1016/j.celrep.2016.12.016>.
266. Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, Wang W, Felczak K, van der Laan LJ, Pankiewicz KW, van der Eijk AA, Bijvelds M, Sprengers D, de Jonge H, Koopmans MP, Metselaar HJ, Peppelenbosch MP, Pan Q. 2016. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. *Antiviral Res* 133:41–49. <https://doi.org/10.1016/j.antiviral.2016.07.017>.
  267. Senger S, Ingano L, Freire R, Anselmo A, Zhu W, Sadreyev R, Walker WA, Fasano A. 2018. Human fetal-derived enterospheres provide insights on intestinal development and a novel model to study necrotizing enterocolitis (NEC). *Cell Mol Gastroenterol Hepatol* 5:549–568. <https://doi.org/10.1016/j.jcmgh.2018.01.014>.
  268. Nickerson KP, Senger S, Zhang Y, Lima R, Patel S, Ingano L, Flavahan WA, Kumar DKV, Fraser CM, Faherty CS, Szein MB, Fiorentino M, Fasano A. 2018. Salmonella Typhi colonization provokes extensive transcriptional changes aimed at evading host mucosal immune defense during early infection of human intestinal tissue. *EBioMedicine* 31:92–109. <https://doi.org/10.1016/j.ebiom.2018.04.005>.
  269. Chen YW, Huang SX, de Carvalho A, Ho SH, Islam MN, Volpi S, Notarangelo LD, Ciancanelli M, Casanova JL, Bhattacharya J, Liang AF, Palermo LM, Porotto M, Moscona A, Snoeck HW. 2017. A three-dimensional model of human lung development and disease from pluripotent stem cells. *Nat Cell Biol* 19:542–549. <https://doi.org/10.1038/ncb3510>.
  270. Dye BR, Hill DR, Ferguson MA, Tsai YH, Nagy MS, Dyal R, Wells JM, Mayhew CN, Nattiv R, Klein OD, White ES, Deutsch GH, Spence JR. 2015. In vitro generation of human pluripotent stem cell derived lung organoids. *Elife* 4:e05098. <https://doi.org/10.7554/eLife.05098>.
  271. Firth AL, Dargitz CT, Qualls SJ, Menon T, Wright R, Singer O, Gage FH, Khanna A, Verma IM. 2014. Generation of multiciliated cells in functional airway epithelia from human induced pluripotent stem cells. *Proc Natl Acad Sci U S A* 111:E1723–E1730. <https://doi.org/10.1073/pnas.1403470111>.
  272. Hegab AE, Arai D, Gao J, Kuroda A, Yasuda H, Ishii M, Naoki K, Soejima K, Betsuyaku T. 2015. Mimicking the niche of lung epithelial stem cells and characterization of several effectors of their in vitro behavior. *Stem Cell Res* 15:109–121. <https://doi.org/10.1016/j.scr.2015.05.005>.
  273. Nikolić MZ, Rawlins EL. 2017. Lung organoids and their use to study cell-cell interaction. *Curr Pathobiol Rep* 5:223–231. <https://doi.org/10.1007/s40139-017-0137-7>.
  274. Shen Y, Chen L, Wang M, Lin D, Liang Z, Song P, Yuan Q, Tang H, Li W, Duan K, Liu B, Zhao G, Wang Y. 2017. Flagellar hooks and hook protein FlgE participate in host-microbe interactions at immunological level. *Sci Rep* 7:1433. <https://doi.org/10.1038/s41598-017-01619-1>.
  275. Bartfeld S, Bayram T, van de Wetering M, Huch M, Begthel H, Kujala P, Vries R, Peters PJ, Clevers H. 2015. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. *Gastroenterology* 148:126–136.e6. <https://doi.org/10.1053/j.gastro.2014.09.042>.
  276. Mahe MM, Aihara E, Schumacher MA, Zavros Y, Montrose MH, Helmrath MA, Sato T, Shroyer NF. 2013. Establishment of gastrointestinal epithelial organoids. *Curr Protoc Mouse Biol* 3:217–240. <https://doi.org/10.1002/9780470942390.mo130179>.
  277. Bertaux-Skeirik N, Feng R, Schumacher MA, Li J, Mahe MM, Engevik AC, Javier JE, Peek RM, Jr, Ottemann K, Orian-Rousseau V, Boivin GP, Helmrath MA, Zavros Y. 2015. CD44 plays a functional role in Helicobacter pylori-induced epithelial cell proliferation. *PLoS Pathog* 11: e1004663. <https://doi.org/10.1371/journal.ppat.1004663>.
  278. McCracken KW, Cata EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich BE, Tsai YH, Mayhew CN, Spence JR, Zavros Y, Wells JM. 2014. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. *Nature* 516:400–404. <https://doi.org/10.1038/nature13863>.
  279. Sigal M, Rothenberg ME, Logan CY, Lee JY, Honaker RW, Cooper RL, Passarelli B, Camorlinga M, Bouley DM, Alvarez G, Nusse R, Torres J, Amieva MR. 2015. Helicobacter pylori activates and expands Lgr5+ stem cells through direct colonization of the gastric glands. *Gastroenterology* 148:1392–1404.e21. <https://doi.org/10.1053/j.gastro.2015.02.049>.
  280. McCracken KW, Aihara E, Martin B, Crawford CM, Broda T, Treguier J, Zhang X, Shannon JM, Montrose MH, Wells JM. 2017. Wnt/beta-catenin promotes gastric fundus specification in mice and humans. *Nature* 541:182–187. <https://doi.org/10.1038/nature21021>.
  281. Schlaermann P, Toelle B, Berger H, Schmidt SC, Glanemann M, Orde-mann J, Bartfeld S, Mollenkopf HJ, Meyer TF. 2016. A novel human gastric primary cell culture system for modelling Helicobacter pylori infection in vitro. *Gut* 65:202–213. <https://doi.org/10.1136/gutjnl-2014-307949>.
  282. Burkitt MD, Duckworth CA, Williams JM, Pritchard DM. 2017. Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models. *Dis Model Mech* 10:89–104. <https://doi.org/10.1242/dmm.027649>.
  283. Li ML, Aggeler J, Farson DA, Hatier C, Hassell J, Bissell MJ. 1987. Influence of a reconstituted basement membrane and its components on casein gene expression and secretion in mouse mammary epithelial cells. *Proc Natl Acad Sci U S A* 84:136–140.
  284. Vidi PA, Bissell MJ, Lelievre SA. 2013. Three-dimensional culture of human breast epithelial cells: the how and the why. *Methods Mol Biol* 945:193–219. [https://doi.org/10.1007/978-1-62703-125-7\\_13](https://doi.org/10.1007/978-1-62703-125-7_13).
  285. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, Jackson AP, Knoblich JA. 2013. Cerebral organoids model human brain development and microcephaly. *Nature* 501:373–379. <https://doi.org/10.1038/nature12517>.
  286. Eiraku M, Watanabe K, Matsuo-Takasaki M, Kawada M, Yonemura S, Matsumura M, Wataya T, Nishiyama A, Muguruma K, Sasai Y. 2008. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. *Cell Stem Cell* 3:519–532. <https://doi.org/10.1016/j.stem.2008.09.002>.
  287. Qian X, Nguyen Ha N, Song Mingxi M, Hadiono C, Ogden Sarah C, Hammack C, Yao B, Hamersky Gregory R, Jacob F, Zhong C, Yoon K-J, Jeang W, Lin L, Li Y, Thakor J, Berg Daniel A, Zhang C, Kang E, Chickering M, Nauen D, Ho C-Y, Wen Z, Christian Kimberly M, Shi P-Y, Maher Brady J, Wu H, Jin P, Tang H, Song H, Ming G-I. 2016. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. *Cell* 165:1238–1254. <https://doi.org/10.1016/j.cell.2016.04.032>.
  288. Huch M, Dorrell C, Boj SF, van Es JH, Li VSW, van de Wetering M, Sato T, Hamer K, Sasaki N, Finegold MJ, Haft A, Vries RG, Grompe M, Clevers H. 2013. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. *Nature* 494:247–250. <https://doi.org/10.1038/nature11826>.
  289. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang R-R, Ueno Y, Zheng Y-W, Koike N, Aoyama S, Adachi Y, Taniguchi H. 2013. Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature* 499:481–484. <https://doi.org/10.1038/nature12271>.
  290. Huch M, Bonfanti P, Boj SF, Sato T, Loomans CJM, van de Wetering M, Sojoodi M, Li VSW, Schuijers J, Gracanin A, Ringnald F, Begthel H, Hamer K, Mulder J, van Es JH, de Koning E, Vries RGJ, Heimberg H, Clevers H. 2013. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. *EMBO J* 32: 2708–2721. <https://doi.org/10.1038/emboj.2013.204>.
  291. Greggio C, De Franceschi F, Figueiredo-Larsen M, Gobaa S, Ranga A, Semb H, Lutolf M, Grapin-Botton A. 2013. Artificial three-dimensional niches deconstruct pancreas development in vitro. *Development* 140: 4452–4462. <https://doi.org/10.1242/dev.096628>.
  292. Scanu T, Spaapen RM, Bakker JM, Pratap CB, Wu LE, Hofland I, Broeks A, Shukla VK, Kumar M, Janssen H, Song JY, Neeffjes-Borst EA, te Riele H, Holden DW, Nath G, Neeffjes J. 2015. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. *Cell Host Microbe* 17:763–774. <https://doi.org/10.1016/j.chom.2015.05.002>.
  293. Eiraku M, Takata N, Ishibashi H, Kawada M, Sakakura E, Okuda S, Sekiguchi K, Adachi T, Sasai Y. 2011. Self-organizing optic-cup morphogenesis in three-dimensional culture. *Nature* 472:51–56. <https://doi.org/10.1038/nature09941>.
  294. Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H, Nishinakamura R. 2014. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. *Cell Stem Cell* 14:53–67. <https://doi.org/10.1016/j.stem.2013.11.010>.
  295. Karthaus Wouter R, laquinta Phillip J, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling Catherine M, Gao D, Begthel H, Sachs N, Vries Robert GJ, Cuppen E, Chen Y, Sawyers Charles L, Clevers Hans C. 2014. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. *Cell* 159:163–175. <https://doi.org/10.1016/j.cell.2014.08.017>.

296. Chua CW, Shibata M, Lei M, Toivanen R, Barlow LJ, Bergren SK, Badani KK, McKiernan JM, Benson MC, Hibshoosh H, Shen MM. 2014. Single luminal epithelial progenitors can generate prostatic organoids in culture. *Nat Cell Biol* 16:951–961. <https://doi.org/10.1038/ncb3047>.
297. Zhu Y, Yang Y, Guo J, Dai Y, Ye L, Qiu J, Zeng Z, Wu X, Xing Y, Long X, Wu X, Ye L, Wang S, Li H. 2017. Ex vivo 2D and 3D HSV-2 infection model using human normal vaginal epithelial cells. *Oncotarget* 8:15267–15282.
298. Kessler M, Hoffmann K, Brinkmann V, Thieck O, Jackisch S, Toelle B, Berger H, Mollenkopf HJ, Mangler M, Sehoul J, Fotopoulou C, Meyer TF. 2015. The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. *Nat Commun* 6:8989. <https://doi.org/10.1038/ncomms9989>.
299. Ghaedi M, Calle EA, Mendez JJ, Gard AL, Balestrini J, Booth A, Bove PF, Gui L, White ES, Niklason LE. 2013. Human iPSC cell-derived alveolar epithelium repopulates lung extracellular matrix. *J Clin Invest* 123:4950–4962. <https://doi.org/10.1172/JCI68793>.
300. Finkbeiner SR, Freeman JJ, Wieck MM, El-Nachef W, Altheim CH, Tsai YH, Huang S, Dyal R, White ES, Grikscheit TC, Teitelbaum DH, Spence JR. 2015. Generation of tissue-engineered small intestine using embryonic stem cell-derived human intestinal organoids. *Biol Open* 4:1462–1472. <https://doi.org/10.1242/bio.013235>.
301. Quantius J, Schmoltdt C, Vazquez-Armendariz AI, Becker C, El Agha E, Wilhelm J, Morty RE, Vadasz I, Mayer K, Gattenloehner S, Fink L, Matrosovich M, Li X, Seeger W, Lohmeyer J, Bellusci S, Herold S. 2016. Influenza virus infects epithelial stem/progenitor cells of the distal lung: impact on Fgfr2b-driven epithelial repair. *PLoS Pathog* 12:e1005544. <https://doi.org/10.1371/journal.ppat.1005544>.
302. Al Shammari B, Shiomi T, Tezera L, Bielecka MK, Workman V, Sathyamoorthy T, Mauri F, Jayasinghe SN, Robertson BD, D'Armiento J, Friedland JS, Elkington PT. 2015. The extracellular matrix regulates granuloma necrosis in tuberculosis. *J Infect Dis* 212:463–473. <https://doi.org/10.1093/infdis/jiv076>.
303. Clevers H. 2016. Modeling development and disease with organoids. *Cell* 165:1586–1597. <https://doi.org/10.1016/j.cell.2016.05.082>.
304. Lancaster MA, Knoblich JA. 2014. Organogenesis in a dish: modeling development and disease using organoid technologies. *Science* 345:1247125. <https://doi.org/10.1126/science.1247125>.
305. Bissell MJ, Labarge MA. 2005. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? *Cancer Cell* 7:17–23. <https://doi.org/10.1016/j.ccr.2004.12.013>.
306. Chingwaru W, Glashoff RH, Vidmar J, Kapewangolo P, Sampson SL. 2016. Mammalian cell cultures as models for Mycobacterium tuberculosis-human immunodeficiency virus (HIV) interaction studies: a review. *Asian Pac J Trop Med* 9:832–838. <https://doi.org/10.1016/j.apjtm.2016.07.002>.
307. Dutta D, Heo I, Clevers H. 2017. Disease modeling in stem cell-derived 3D organoid systems. *Trends Mol Med* 23:393–410. <https://doi.org/10.1016/j.molmed.2017.02.007>.
308. Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, Burgin G, Delorey TM, Howitt MR, Katz Y, Tirosh I, Beyaz S, Dionne D, Zhang M, Raychowdhury R, Garrett WS, Rozenblatt-Rosen O, Shi HN, Yilmaz O, Xavier RJ, Regev A. 2017. A single-cell survey of the small intestinal epithelium. *Nature* 551:333–339. <https://doi.org/10.1038/nature24489>.
309. Foulke-Abel J, In J, Kovbasnjuk O, Zachos NC, Ettayebi K, Blutt SE, Hyser JM, Zeng XL, Crawford SE, Broughman JR, Estes MK, Donowitz M. 2014. Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract. *Exp Biol Med* 239:1124–1134. <https://doi.org/10.1177/1535370214529398>.
310. Lukovac S, Belzer C, Pellis L, Keijsers BJ, de Vos WM, Montijn RC, Roeselers G. 2014. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids. *mBio* 5:e01438-14. <https://doi.org/10.1128/mBio.01438-14>.
311. Naito T, Mulet C, De Castro C, Molinaro A, Saffarian A, Nigro G, Bérard M, Clerc M, Pedersen AB, Sansonetti PJ, Pédrón T. 2017. Lipopolysaccharide from crypt-specific core microbiota modulates the colonic epithelial proliferation-to-differentiation balance. *mBio* 8:e01680-17. <https://doi.org/10.1128/mBio.01680-17>.
312. Nigro G, Rossi R, Commere PH, Jay P, Sansonetti PJ. 2014. The cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut epithelial regeneration. *Cell Host Microbe* 15:792–798. <https://doi.org/10.1016/j.chom.2014.05.003>.
313. Noel G, Baetz NW, Staab JF, Donowitz M, Kovbasnjuk O, Pasetti MF, Zachos NC. 2017. A primary human macrophage-enteroid co-culture model to investigate gut physiology and host-pathogen interactions. *Sci Rep* 7:45270. <https://doi.org/10.1038/srep45270>.
314. Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, Neill FH, Blutt SE, Zeng XL, Qu L, Kou B, Opekun AR, Burrin D, Graham DY, Ramani S, Atmar RL, Estes MK. 2016. Replication of human noroviruses in stem cell-derived human enteroids. *Science* 353:1387–1393. <https://doi.org/10.1126/science.aaf5211>.
315. Finkbeiner SR, Zeng XL, Utama B, Atmar RL, Shroyer NF, Estes MK. 2012. Stem cell-derived human intestinal organoids as an infection model for rotaviruses. *mBio* 3:e00159-12. <https://doi.org/10.1128/mBio.00159-12>.
316. Huang L, Hou Q, Ye L, Yang Q, Yu Q. 2017. Crosstalk between H9N2 avian influenza virus and crypt-derived intestinal organoids. *Vet Res* 48:71. <https://doi.org/10.1186/s13567-017-0478-6>.
317. Zhang D, Tan M, Zhong W, Xia M, Huang P, Jiang X. 2017. Human intestinal organoids express histo-blood group antigens, bind norovirus VLPs, and support limited norovirus replication. *Sci Rep* 7:12621. <https://doi.org/10.1038/s41598-017-12736-2>.
318. Zhou J, Li C, Zhao G, Chu H, Wang D, Yan HH-N, Poon VK-M, Wen L, Wong BH-Y, Zhao X, Chiu MC, Yang D, Wang Y, Au-Yeung RKH, Chan IH-Y, Sun S, Chan JF-W, To KK-W, Memish ZA, Corman VM, Drosten C, Hung IF-N, Zhou Y, Leung SY, Yuen K-Y. 2017. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. *Science Advances* 3:ea04966. <https://doi.org/10.1126/sciadv.aao4966>.
319. Burger E, Araujo A, Lopez-Yglesias A, Rajala MW, Geng L, Levine B, Hooper LV, Burstein E, Yarovinsky F. 2018. Loss of Paneth cell autophagy causes acute susceptibility to Toxoplasma gondii-mediated inflammation. *Cell Host Microbe* 23:177–190.e4. <https://doi.org/10.1016/j.chom.2018.01.001>.
320. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haeghebarth A, Korving J, Begthel H, Peters PJ, Clevers H. 2007. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 449:1003–1007. <https://doi.org/10.1038/nature06196>.
321. Jung P, Sato T, Merlos-Suarez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E, Clevers H, Batlle E. 2011. Isolation and in vitro expansion of human colonic stem cells. *Nat Med* 17:1225–1227. <https://doi.org/10.1038/nm.2470>.
322. Hannan NR, Fordham RP, Syed YA, Moignard V, Berry A, Bautista R, Hanley NA, Jensen KB, Vallier L. 2013. Generation of multipotent foregut stem cells from human pluripotent stem cells. *Stem Cell Rep* 1:293–306. <https://doi.org/10.1016/j.stemcr.2013.09.003>.
323. Kleinman HK, Martin GR. 2005. Matrigel: basement membrane matrix with biological activity. *Semin Cancer Biol* 15:378–386. <https://doi.org/10.1016/j.semcancer.2005.05.004>.
324. Orkin RW, Gehron P, McGoodwin EB, Martin GR, Valentine T, Swam R. 1977. A murine tumor producing a matrix of basement membrane. *J Exp Med* 145:204–220.
325. Stelzner M, Helmrath M, Dunn JC, Henning SJ, Houchen CW, Kuo C, Lynch J, Li L, Magness ST, Martin MG, Wong MH, Yu J, Consortium NIHISC. 2012. A nomenclature for intestinal in vitro cultures. *Am J Physiol Gastrointest Liver Physiol* 302:G1359–G1363. <https://doi.org/10.1152/ajpgi.00493.2011>.
326. Nossol C, Dising AK, Walk N, Faber-Zuschratter H, Hartig R, Post A, Kluess J, Rothkotter HJ, Kahlert S. 2011. Air-liquid interface cultures enhance the oxygen supply and trigger the structural and functional differentiation of intestinal porcine epithelial cells (IPEC). *Histochem Cell Biol* 136:103–115. <https://doi.org/10.1007/s00418-011-0826-y>.
327. Drummond CG, Bolock AM, Ma C, Luke CJ, Good M, Coyne CB. 2017. Enteroviruses infect human enteroids and induce antiviral signaling in a cell lineage-specific manner. *Proc Natl Acad Sci U S A* 114:1672–1677. <https://doi.org/10.1073/pnas.1617363114>.
328. van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, McLaren-Douglas A, Blokkes J, Jaksani S, Bartfeld S, Volckman R, van Sluis P, Li VS, Seepo S, Sekhar Pedamallu C, Cibulskis K, Carter SL, McKenna A, Lawrence MS, Lichtenstein L, Stewart C, Koster J, Versteeg R, van Oudenaarden A, Saez-Rodriguez J, Vries RG, Getz G, Wessels L, Stratton MR, McDermott U, Meyerson M, Garnett MJ, Clevers H. 2015. Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell* 161:933–945. <https://doi.org/10.1016/j.cell.2015.03.053>.
329. Kingwell K. 2016. 3D cell technologies head to the R&D assembly line. *Nat Rev Drug Discov* 16:6–7. <https://doi.org/10.1038/nrd.2016.282>.
330. Noordhoek J, Gulmans V, van der Ent K, Beekman JM. 2016. Intestinal



- organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration. *Curr Opin Pulm Med* 22: 610–616. <https://doi.org/10.1097/MCP.0000000000000315>.
331. Ohno H, Kanaya T, Williams IR. 2012. M cell differentiation: distinct lineage or phenotypic transition? *Salmonella* provides answers. *Cell Host Microbe* 12:607–609. <https://doi.org/10.1016/j.chom.2012.11.003>.
  332. Tahoun A, Mahajan S, Paxton E, Malterer G, Donaldson DS, Wang D, Tan A, Gillespie TL, O'Shea M, Roe AJ, Shaw DJ, Gally DL, Lengeling A, Mabbott NA, Haas J, Mahajan A. 2012. *Salmonella* transforms follicle-associated epithelial cells into M cells to promote intestinal invasion. *Cell Host Microbe* 12:645–656. <https://doi.org/10.1016/j.chom.2012.10.009>.
  333. Kernéis S, Bogdanova A, Kraehenbuhl J-P, Pringault E. 1997. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. *Science* 277:949–952. <https://doi.org/10.1126/science.277.5328.949>.
  334. Kasendra M, Tovaglieri A, Sontheimer-Phelps A, Jalili-Firoozinezhad S, Bein A, Chalkiadaki A, Scholl W, Zhang C, Rickner H, Richmond CA, Li H, Breault DT, Ingber DE. 2018. Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids. *Sci Rep* 8:2871. <https://doi.org/10.1038/s41598-018-21201-7>.
  335. Bhatia SN, Ingber DE. 2014. Microfluidic organs-on-chips. *Nat Biotechnol* 32:760–772. <https://doi.org/10.1038/nbt.2989>.
  336. Benam KH, Dauth S, Hassell B, Herland A, Jain A, Jang KJ, Karalis K, Kim HJ, MacQueen L, Mahmoodian R, Musah S, Torisawa YS, van der Meer AD, Villenave R, Yadid M, Parker KK, Ingber DE. 2015. Engineered in vitro disease models. *Annu Rev Pathol* 10:195–262. <https://doi.org/10.1146/annurev-pathol-012414-040418>.
  337. Selimovic S, Dokmeci MR, Khademhosseini A. 2013. Organs-on-a-chip for drug discovery. *Curr Opin Pharmacol* 13:829–833. <https://doi.org/10.1016/j.coph.2013.06.005>.
  338. Huh D, Torisawa YS, Hamilton GA, Kim HJ, Ingber DE. 2012. Microengineered physiological biomimicry: organs-on-chips. *Lab Chip* 12: 2156–2164. <https://doi.org/10.1039/c2lc40089h>.
  339. Esch EW, Bahinski A, Huh D. 2015. Organs-on-chips at the frontiers of drug discovery. *Nat Rev Drug Discov* 14:248–260. <https://doi.org/10.1038/nrd4539>.
  340. Kim HJ, Huh D, Hamilton G, Ingber DE. 2012. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. *Lab Chip* 12:2165–2174. <https://doi.org/10.1039/c2lc40074j>.
  341. Kim HJ, Ingber DE. 2013. Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation. *Integr Biol (Camb)* 5:1130–1140. <https://doi.org/10.1039/c3ib40126j>.
  342. Kim HJ, Li H, Collins JJ, Ingber DE. 2016. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. *Proc Natl Acad Sci U S A* 113:E7–E15. <https://doi.org/10.1073/pnas.1522193112>.
  343. Villenave R, Wales SQ, Hamkins-Indik T, Papafragkou E, Weaver JC, Ferrante TC, Bahinski A, Elkins CA, Kulka M, Ingber DE. 2017. Human gut-on-a-chip supports polarized infection of coxsackie B1 virus in vitro. *PLoS One* 12:e0169412. <https://doi.org/10.1371/journal.pone.0169412>.
  344. Huh D, Hamilton GA, Ingber DE. 2011. From 3D cell culture to organs-on-chips. *Trends Cell Biol* 21:745–754. <https://doi.org/10.1016/j.tcb.2011.09.005>.
  345. Huh D, Kim HJ, Fraser JP, Shea DE, Khan M, Bahinski A, Hamilton GA, Ingber DE. 2013. Microfabrication of human organs-on-chips. *Nat Protoc* 8:2135–2157. <https://doi.org/10.1038/nprot.2013.137>.
  346. Folch A, Toner M. 2000. Microengineering of cellular interactions. *Annu Rev Biomed Eng* 2:227–256. <https://doi.org/10.1146/annurev.bioeng.2.1.227>.
  347. Khademhosseini A, Langer R, Borenstein J, Vacanti JP. 2006. Microscale technologies for tissue engineering and biology. *Proc Natl Acad Sci U S A* 103:2480–2487. <https://doi.org/10.1073/pnas.0507681102>.
  348. Whitesides GM, Ostuni E, Takayama S, Jiang X, Ingber DE. 2001. Soft lithography in biology and biochemistry. *Annu Rev Biomed Eng* 3:335–373. <https://doi.org/10.1146/annurev.bioeng.3.1.335>.
  349. Whitesides GM. 2006. The origins and the future of microfluidics. *Nature* 442:368–373. <https://doi.org/10.1038/nature05058>.
  350. Halldorsson S, Lucumi E, Gomez-Sjoberg R, Fleming RM. 2015. Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices. *Biosens Bioelectron* 63:218–231. <https://doi.org/10.1016/j.bios.2014.07.029>.
  351. Sackmann EK, Fulton AL, Beebe DJ. 2014. The present and future role of microfluidics in biomedical research. *Nature* 507:181–189. <https://doi.org/10.1038/nature13118>.
  352. Yi H-G, Lee H, Cho D-W. 2017. 3D printing of organs-on-chips. *Bioengineering* 4:10. <https://doi.org/10.3390/bioengineering4010010>.
  353. Henry OYF, Villenave R, Cronce MJ, Leineweber WD, Benz MA, Ingber DE. 2017. Organs-on-chips with integrated electrodes for trans-epithelial electrical resistance (TEER) measurements of human epithelial barrier function. *Lab Chip* 17:2264–2271. <https://doi.org/10.1039/C7LC00155J>.
  354. Kim J, Hegde M, Jayaraman A. 2010. Co-culture of epithelial cells and bacteria for investigating host-pathogen interactions. *Lab Chip* 10: 43–50. <https://doi.org/10.1039/B911367C>.
  355. Esch MB, Sung JH, Yang J, Yu C, Yu J, March JC, Shuler ML. 2012. On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic 'body-on-a-chip' devices. *Biomed Microdevices* 14:895–906. <https://doi.org/10.1007/s10544-012-9669-0>.
  356. Mahler GJ, Esch MB, Glahn RP, Shuler ML. 2009. Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity. *Biotechnol Bioeng* 104:193–205. <https://doi.org/10.1002/bit.22366>.
  357. Huh D, Fujioka H, Tung YC, Futai N, Paine R, III, Grotberg JB, Takayama S. 2007. Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in microfluidic airway systems. *Proc Natl Acad Sci U S A* 104:18886–18891. <https://doi.org/10.1073/pnas.0610868104>.
  358. Huh D, Leslie DC, Matthews BD, Fraser JP, Jurek S, Hamilton GA, Thorneloe KS, McAlexander MA, Ingber DE. 2012. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. *Sci Transl Med* 4:159ra147. <https://doi.org/10.1126/scitranslmed.3004249>.
  359. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. 2010. Reconstituting organ-level lung functions on a chip. *Science* 328:1662–1668. <https://doi.org/10.1126/science.1188302>.
  360. Huh DD. 2015. A human breathing lung-on-a-chip. *Ann Am Thorac Soc* 12(Suppl 1):S42–S44. <https://doi.org/10.1513/AnnalsATS.201410-442MG>.
  361. Tavana H, Zamankhan P, Christensen PJ, Grotberg JB, Takayama S. 2011. Epithelium damage and protection during reopening of occluded airways in a physiologic microfluidic pulmonary airway model. *Biomed Microdevices* 13:731–742. <https://doi.org/10.1007/s10544-011-9543-5>.
  362. Kane BJ, Zinner MJ, Yarmush ML, Toner M. 2006. Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes. *Anal Chem* 78:4291–4298. <https://doi.org/10.1021/ac051856v>.
  363. Lee PJ, Hung PJ, Lee LP. 2007. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. *Biotechnol Bioeng* 97:1340–1346. <https://doi.org/10.1002/bit.21360>.
  364. Chao P, Maguire T, Novik E, Cheng KC, Yarmush ML. 2009. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. *Biochem Pharmacol* 78:625–632. <https://doi.org/10.1016/j.bcp.2009.05.013>.
  365. Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. 2010. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. *Biochem Pharmacol* 79:1036–1044. <https://doi.org/10.1016/j.bcp.2009.11.010>.
  366. Legendre A, Baudoin R, Alberto G, Paullier P, Naudot M, Bricks T, Brocheton J, Jacques S, Cotton J, Leclerc E. 2013. Metabolic characterization of primary rat hepatocytes cultivated in parallel microfluidic biochips. *J Pharm Sci* 102:3264–3276. <https://doi.org/10.1002/jps.23466>.
  367. Cheng S, Prot JM, Leclerc E, Bois FY. 2012. Zonation related function and ubiquitination regulation in human hepatocellular carcinoma cells in dynamic vs. static culture conditions. *BMC Genomics* 13:54. <https://doi.org/10.1186/1471-2164-13-54>.
  368. Sivaraman A, Leach JK, Townsend S, Iida T, Hogan BJ, Stolz DB, Fry R, Samson LD, Tannenbaum SR, Griffith LG. 2005. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. *Curr Drug Metab* 6:569–591. <https://doi.org/10.2174/138920005774832632>.
  369. Toh YC, Lim TC, Tai D, Xiao G, van Noort D, Yu H. 2009. A microfluidic 3D hepatocyte chip for drug toxicity testing. *Lab Chip* 9:2026–2035. <https://doi.org/10.1039/b900912d>.
  370. Baudoin R, Griscom L, Monge M, Legallais C, Leclerc E. 2007. Development of a renal microchip for in vitro distal tubule models. *Biotechnol Prog* 23:1245–1253. <https://doi.org/10.1021/bp0603513>.

371. Jang KJ, Mehr AP, Hamilton GA, McPartlin LA, Chung S, Suh KY, Ingber DE. 2013. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. *Integr Biol (Camb)* 5:1119–1129. <https://doi.org/10.1039/c3ib40049b>.
372. Jang KJ, Suh KY. 2010. A multi-layer microfluidic device for efficient culture and analysis of renal tubular cells. *Lab Chip* 10:36–42. <https://doi.org/10.1039/B907515A>.
373. Agarwal A, Goss JA, Cho A, McCain ML, Parker KK. 2013. Microfluidic heart on a chip for higher throughput pharmacological studies. *Lab Chip* 13:3599–3608. <https://doi.org/10.1039/c3lc50350j>.
374. Khanal G, Chung K, Solis-Wever X, Johnson B, Pappas D. 2011. Ischemia/reperfusion injury of primary porcine cardiomyocytes in a low-shear microfluidic culture and analysis device. *Analyst* 136: 3519–3526. <https://doi.org/10.1039/c0an00845a>.
375. Grosberg A, Alford PW, McCain ML, Parker KK. 2011. Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. *Lab Chip* 11:4165–4173. <https://doi.org/10.1039/c1lc20557a>.
376. Cheng W, Klauke N, Sedgwick H, Smith GL, Cooper JM. 2006. Metabolic monitoring of the electrically stimulated single heart cell within a microfluidic platform. *Lab Chip* 6:1424–1431. <https://doi.org/10.1039/b608202e>.
377. Giridharan GA, Nguyen M-D, Estrada R, Parichehreh V, Hamid T, Ismahil MA, Prabhu SD, Sethu P. 2010. Microfluidic cardiac cell culture model ( $\mu$ CCCM). *Anal Chem* 82:7581–7587. <https://doi.org/10.1021/ac1012893>.
378. Puleo CM, McIntosh Ambrose W, Takezawa T, Elisseeff J, Wang TH. 2009. Integration and application of vitrified collagen in multilayered microfluidic devices for corneal microtissue culture. *Lab Chip* 9:3221–3227. <https://doi.org/10.1039/b908332d>.
379. O'Neill AT, Monteiro-Riviere NA, Walker GM. 2008. Characterization of microfluidic human epidermal keratinocyte culture. *Cytotechnology* 56:197–207. <https://doi.org/10.1007/s10616-008-9149-9>.
380. Xiao RR, Zeng WJ, Li YT, Zou W, Wang L, Pei XF, Xie M, Huang WH. 2013. Simultaneous generation of gradients with gradually changed slope in a microfluidic device for quantifying axon response. *Anal Chem* 85: 7842–7850. <https://doi.org/10.1021/ac4022055>.
381. Tsantoulas C, Farmer C, Machado P, Baba K, McMahon SB, Raouf R. 2013. Probing functional properties of nociceptive axons using a microfluidic culture system. *PLoS One* 8:e80722. <https://doi.org/10.1371/journal.pone.0080722>.
382. Shi M, Majumdar D, Gao Y, Brewer BM, Goodwin CR, McLean JA, Li D, Webb DJ. 2013. Glia co-culture with neurons in microfluidic platforms promotes the formation and stabilization of synaptic contacts. *Lab Chip* 13:3008–3021. <https://doi.org/10.1039/c3lc50249j>.
383. Shayan G, Shuler ML, Lee KH. 2011. The effect of astrocytes on the induction of barrier properties in aortic endothelial cells. *Biotechnol Prog* 27:1137–1145. <https://doi.org/10.1002/btpr.620>.
384. Park SH, Sim WY, Min BH, Yang SS, Khademhosseini A, Kaplan DL. 2012. Chip-based comparison of the osteogenesis of human bone marrow and adipose tissue-derived mesenchymal stem cells under mechanical stimulation. *PLoS One* 7:e46689. <https://doi.org/10.1371/journal.pone.0046689>.
385. Zhang Y, Gazit Z, Pelled G, Gazit D, Vunjak-Novakovic G. 2011. Patterning osteogenesis by inducible gene expression in microfluidic culture systems. *Integr Biol (Camb)* 3:39–47. <https://doi.org/10.1039/C0IB00053A>.
386. Xiao S, Coppeta JR, Rogers HB, Isenberg BC, Zhu J, Olalekan SA, McKinnon KE, Dokic D, Rashedi AS, Haiseneder DJ, Malpani SS, Arnold-Murray CA, Chen K, Jiang M, Bai L, Nguyen CT, Zhang J, Laronda MM, Hope TJ, Maniar KP, Pavone ME, Avram MJ, Sefton EC, Getsios S, Burdette JE, Kim JJ, Borenstein JT, Woodruff TK. 2017. A microfluidic culture model of the human reproductive tract and 28-day menstrual cycle. *Nat Commun* 8:14584. <https://doi.org/10.1038/ncomms14584>.
387. Griep LM, Wolbers F, de Wagenaar B, ter Braak PM, Weksler BB, Romero IA, Couraud PO, Vermes I, van der Meer AD, van den Berg A. 2013. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. *Biomed Microdevices* 15:145–150. <https://doi.org/10.1007/s10544-012-9699-7>.
388. Booth R, Kim H. 2012. Characterization of a microfluidic in vitro model of the blood-brain barrier (muBBB). *Lab Chip* 12:1784–1792. <https://doi.org/10.1039/c2lc40094d>.
389. van der Helm MW, van der Meer AD, Eijkel JC, van den Berg A, Segerink LI. 2016. Microfluidic organ-on-chip technology for blood-brain barrier research. *Tissue Barriers* 4:e1142493. <https://doi.org/10.1080/21688370.2016.1142493>.
390. Liu MC, Shih GC, Wu JG, Weng TW, Wu CY, Lu JC, Tung YC. 2013. Electrofluidic pressure sensor embedded microfluidic device: a study of endothelial cells under hydrostatic pressure and shear stress combinations. *Lab Chip* 13:1743–1753. <https://doi.org/10.1039/c3lc41414k>.
391. Hasenberger T, Muhleder S, Dotzler A, Bauer S, Labuda K, Holthöner W, Redl H, Lauster R, Marx U. 2015. Emulating human microcapillaries in a multi-organ-chip platform. *J Biotechnol* 216:1–10. <https://doi.org/10.1016/j.jbiotec.2015.09.038>.
392. Shin M, Matsuda K, Ishii O, Terai H, Kaazempur-Mofrad M, Borenstein J, Detmar M, Vacanti JP. 2004. Endothelialized networks with a vascular geometry in microfabricated poly(dimethyl siloxane). *Biomed Microdevices* 6:269–278. <https://doi.org/10.1023/B:BMMD.0000048559.29932.27>.
393. van der Meer AD, Orlova VV, ten Dijke P, van den Berg A, Mummery CL. 2013. Three-dimensional co-cultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. *Lab Chip* 13:3562–3568. <https://doi.org/10.1039/c3lc50435b>.
394. Wikswo JP. 2014. The relevance and potential roles of microphysiological systems in biology and medicine. *Exp Biol Med* 239:1061–1072. <https://doi.org/10.1177/1535370214542068>.
395. Stucki AO, Stucki JD, Hall SR, Felder M, Mermoud Y, Schmid RA, Geiser T, Guenat OT. 2015. A lung-on-a-chip array with an integrated bio-inspired respiration mechanism. *Lab Chip* 15:1302–1310. <https://doi.org/10.1039/C4LC01252F>.
396. Benam KH, Villenave R, Lucchesi C, Varone A, Hubeau C, Lee HH, Alves SE, Salmon M, Ferrante TC, Weaver JC, Bahinski A, Hamilton GA, Ingber DE. 2016. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. *Nat Methods* 13:151–157. <https://doi.org/10.1038/nmeth.3697>.
397. Abaci HE, Shuler ML. 2015. Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling. *Integr Biol (Camb)* 7:383–391. <https://doi.org/10.1039/C4IB00292J>.
398. nobeastsofierce (Contributor). Date unknown. Stock image of intestinal lining and villi [digital image]. Retrieved from <https://www.123rf.com/> (123RF Image ID 55676294). Accessed 8 February 2017.
399. Ivan Moshe (Contributor). Date unknown. Stock image of cells [digital image]. Retrieved from <https://www.shutterstock.com/> (Shutterstock Image ID 174738014). Accessed 23 January 2018.
400. sciencepics (Contributor). Date unknown. Stock image of small and large intestine [digital image]. Retrieved from <https://www.shutterstock.com/> (Shutterstock Image ID 541068199). Accessed 23 January 2018.
401. Kateryna Kon (Contributor). Date unknown. Stock image of human intestine with intestinal bacteria [digital image]. Retrieved from <https://www.shutterstock.com/> (Shutterstock Image ID 400088722). Accessed 23 January 2018.

**Jennifer Barrila** is an Assistant Research Professor at the Biodesign Institute, Arizona State University (ASU). She received her B.S. in biochemistry in 2002 from Syracuse University. In 2008 she received her Ph.D. in biology from Johns Hopkins University, where she structurally characterized the severe acute respiratory syndrome (SARS) coronavirus main protease to facilitate structure-based drug design. Her postdoctoral work at the Biodesign Institute used innovative culture systems to investigate how biomechanical forces regulate host and pathogen responses during infection. In 2010 she was promoted to Assistant Research Scientist and in 2013 to Assistant Research Professor. Her current research involves the development and application of multicellular 3-D models of human intestine to investigate the role of cellular biomechanics in host-pathogen-microbiota interactions. Her biomedical research has flown on several NASA spaceflight missions to the International Space Station to study the influence of biophysical forces on infection. In 2014 she received the Thora W. Halstead Young Investigator's Award.



**Aurélie Crabbé** obtained her Ph.D. in Bioscience Engineering at the Vrije Universiteit Brussel, Belgium. During her Ph.D. studies she received a fellowship of the Belgian American Educational Foundation to perform research in the laboratory of Prof. Cheryl Nickerson at the Biodesign Institute at Arizona State University. She then received a postdoctoral position in the Nickerson lab, where she developed and used physiologically relevant models of the lung mucosa to explore host-pathogen interactions. She is currently a team leader in the Laboratory of Pharmaceutical Microbiology at Ghent University under the tutelage of Prof. Tom Coenye, through an Odysseus fellowship of the Research Foundation Flanders. Her research focuses on understanding how the host, microbiome, and their interactions influence antimicrobial agent efficacy and inflammation in chronic lung infections. To this end, *in vivo*-like models of lung epithelium, the microbiome, or both are used to facilitate translation of *in vitro* results to novel therapeutic approaches.



**Jiseon Yang** is an Alfred P. Sloan postdoctoral fellow (NASA joint program) at the Biodesign Institute, ASU. She received her M.S. in microbiology studying *Salmonella* pathogenesis from Pusan National University (South Korea). She subsequently worked with Dr. Roy Curtiss III and Dr. Josephine Clark-Curtiss (ASU) on developing a 2nd-generation lysis system in recombinant attenuated *Salmonella* vaccines to deliver *Mycobacterium tuberculosis* antigens. She received her Ph.D. in microbiology under Dr. Cheryl Nickerson (ASU), in whose laboratory she characterized virulence, stress, and molecular genetic responses of invasive, multidrug-resistant nontyphoidal *Salmonella* to physiological fluid shear. She was co-first author on the first report of an RWV-derived 3-D intestinal coculture model (epithelial cells and macrophages) to study *Salmonella* pathogenesis. She currently studies how microbes inhabiting built environments influence human health and systems integrity using the International Space Station as a microbial observatory to reveal new insight into how interspecies interactions within microbial populations can adapt/evolve over time.



**Karla Franco** received her bachelor's degree in general science from Pontificia Universidad Católica de Puerto Rico. She became interested in microbial pathogenesis during a year-long NIH training fellowship (ASU PREP). She enrolled in the microbiology Ph.D. program at Arizona State University, where she received a 2-year fellowship from the NIH IMSD program. As a member of the Nickerson laboratory, she has spent the last 3 years investigating the role of mechanotransduction in regulating the phenotypic and molecular genetic responses of *Salmonella Typhimurium*.



**Seth D. Nydam** received his doctorate in veterinary medicine from Cornell University and his Ph.D. from Washington State University. His graduate studies in Dr. Douglas Call's laboratory centered on the type 3 secretion system of *Vibrio parahaemolyticus*, after which he joined Dr. Cheryl Nickerson at Arizona State University for postdoctoral training to explore 3-D cell culture and its interactions with resident microflora and *Salmonella* pathogenesis. He is currently the clinical veterinarian at Arizona State University's Department of Animal Care and Technologies, where he leads the clinical team and provides research support and oversight. His continuing interests include microbial pathogenesis, animal models in infectious disease research, and teaching.



**Rebecca J. Forsyth** received her B.S. in microbiology from Arizona State University in 2008. She first joined the Nickerson laboratory as an undergraduate student, was subsequently hired as an Assistant Research Technologist, and was later promoted to the positions of Associate Research Specialist and Senior Research Specialist. She used a variety of 3-D models, microbes, and model host organisms in her infectious disease research. She was passionate about using "outside-of-the-box" approaches to solve important biomedical health issues, including the use of the spaceflight platform and the RWV bioreactor to study microbial physiology and host-pathogen interactions.



**Richard R. Davis** is a Senior Research Specialist in the Biodesign Center for Immunotherapy, Vaccines, and Virotherapy at Arizona State University. He earned his B.A. in anthropology in 2001 and a B.S. in microbiology in 2007 from Arizona State University. He joined the Nickerson laboratory as an undergraduate student, was subsequently hired as an Assistant Research Technician, and was later promoted to the positions of Research Specialist and Senior Research Specialist. His research over the past 11 years has focused on using both the microgravity platform (including six spaceflight experiments) and the RWV bioreactor to study the effect of physical forces on microbial pathogenesis and host-pathogen interactions.



*Continued next page*

**Sandhya Gangaraju** received her master's degree in biochemistry in 2003 from the University of Ottawa, Canada. In 2003, she joined the National Research Council, Canada, as a research technical officer and viral facility manager in the department of neurogenesis and brain repair. She implemented lentiviral technology to deliver neurotropic factors to neural cells and developed Transwell assays to study neutrophil transmigration through endothelial cells. In 2014, she joined the Biodesign Institute, Arizona State University, as a principal research specialist and compliance officer for the Center for Biosignatures Discovery Automation, where she managed the cell culture facility, led experimental design for students and junior staff members, and optimized working protocols for microfluidic devices for studying three-dimensional tissue environments. Most recently, she joined the Nickerson laboratory as a principal research specialist; at this laboratory, she uses the RWV and the spaceflight platform to study microbial pathogenesis and for 3-D tissue engineering.



**C. Mark Ott** received his B.S. in chemical engineering from the University of Texas at Austin in 1982, his M.B.A. from Louisiana State University in 1989, and his Ph.D. in microbiology from Louisiana State University in 1998. He has published extensively in the areas of microbial ecology in spacecraft, human and microbial responses to spaceflight, and the development of advanced tissue culture models to investigate infectious disease. For the past 20 years, Dr. Ott has served as a technical lead in the Johnson Space Center Microbiology Laboratory, which is responsible for mitigating infectious disease risk during human spaceflight. His responsibilities include the assessment of microbial risk and development of spaceflight requirements based on vehicle and mission architecture as well as crewmember, food, and environmental monitoring.



**Carolyn B. Coyne** completed her Ph.D. at the University of North Carolina at Chapel Hill, where she studied the human respiratory epithelium. She then carried out her postdoctoral fellowship at the Children's Hospital of Philadelphia (CHOP), Philadelphia, PA, and the University of Pennsylvania, Philadelphia, PA, where her research focused on identifying the mechanisms by which enteroviruses invade the gastrointestinal epithelium and blood-brain barrier endothelium. She joined the University of Pittsburgh, Pittsburgh, PA, as a faculty member in 2007; at this institution, her work continued to focus on defining the mechanisms by which viruses breach cellular barriers. Dr. Coyne's laboratory also studies how the human placenta restricts viral infections. Her research interests also include the development of primary and cell line-based models of cellular barriers, focusing on both the gastrointestinal tract and placenta. Her research interests include enteroviruses and flaviviruses, with a particular emphasis on the strategies by which these viruses bypass cellular barriers.



**Mina J. Bissell** is a Distinguished Scientist, the highest rank bestowed at Lawrence Berkeley National Laboratory, and serves as Senior Advisor to the Laboratory Director on Biology. She is also Faculty of four graduate groups in UC Berkeley: Comparative Biochemistry, Endocrinology, Molecular Toxicology, and Bioengineering (UCSF/UCB joint). Having challenged several established paradigms, Bissell is a pioneer in breast cancer research, and her body of work has provided much impetus for the current recognition of the significant role that extracellular matrix signaling and the microenvironment play in gene expression regulation in both normal and malignant cells. Her laboratory developed novel 3-D assays and techniques that demonstrate her signature phrase: after conception, "phenotype is dominant over genotype." Bissell has received numerous honors and awards and is an elected fellow of most U.S. honorary scientific academies. She has published over 400 publications and continues to engage in full-time research, among other scientific activities.



**Cheryl A. Nickerson** is a Professor in the School of Life Sciences at the Biodesign Institute, Arizona State University. She received her Ph.D. in microbiology from Louisiana State University. Her postdoctoral training in *Salmonella* pathogenesis was done with Dr. Roy Curtiss III at Washington University in St. Louis, MO. She initiated her ongoing studies into the connection between cellular biomechanics/mechanotransduction and host-pathogen systems biology after joining the faculty at the Tulane University School of Medicine in 1998. Her development of innovative model pathogenesis systems includes 3-D organotypic tissue culture models to study host-pathogen interactions and approaches that characterize pathogen responses to physiological fluid shear forces encountered in the infected host and in the microgravity environment of spaceflight. She received the Presidential Early Career Award for Scientists and Engineers, NASA's Exceptional Scientific Achievement Medal, is an American Society for Microbiology Distinguished Lecturer, and was selected as a NASA astronaut candidate finalist.

